1
EXHIBIT 10.2
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.
LEXVISION(TM) DATABASE AND COLLABORATION AGREEMENT
BETWEEN
LEXICON GENETICS INCORPORATED
AND
INCYTE GENOMICS, INC.
DATED AS OF JUNE 27, 2001
2
LEXVISION(TM) DATABASE AND COLLABORATION AGREEMENT
THIS LEXVISION(TM) DATABASE AND COLLABORATION AGREEMENT (this
"Agreement") is dated as of June 27, 2001 (the "Effective Date") and is made by
and between LEXICON GENETICS INCORPORATED, a Delaware corporation ("Lexicon"),
and INCYTE GENOMICS, INC., a Delaware corporation ("Incyte"). Lexicon and Incyte
are sometimes referred to herein individually as a "party" and collectively as
the "parties."
RECITALS
WHEREAS, Lexicon has compiled and is continuing to compile the
LexVision(TM) and OmniBank(R) Databases (as hereinafter defined);
WHEREAS, Lexicon owns or has rights to, and expertise in, certain
methods of producing Mutant Mice (as hereinafter defined);
WHEREAS, Incyte desires to obtain non-exclusive access to the LexVision
and OmniBank Databases during the Collaboration Term (as hereinafter defined),
and certain licenses under the Lexicon Patent Rights and the Lexicon Know-How
relating to Designated Drug Targets (in each case, as hereinafter defined), for
purposes of drug discovery research;
WHEREAS, Incyte desires that Lexicon develop, upon request, certain
Mutant Mice having Selected Mutations (as hereinafter defined) for use in such
research;
WHEREAS, Lexicon is willing to grant Incyte non-exclusive access to the
LexVision and OmniBank Databases during the Collaboration Term, and certain
licenses under the Lexicon Patent Rights and/or the Lexicon Know-How relating to
Designated Drug Targets, for purposes of drug discovery research upon the terms
and conditions set forth herein; and
WHEREAS, Lexicon is willing to develop, upon request by Incyte, Mutant
Mice having Selected Mutations for use in drug discovery research upon the terms
and conditions set forth herein;
NOW THEREFORE, in consideration of the premises and of the covenants
herein contained, the parties hereto mutually agree as follows:
Article 1. DEFINITIONS
For purposes of this Agreement, the terms defined in this Article 1
shall have the respective meanings specified below:
1.1 "Academic Collaborator" means a principal investigator, employed at
a university or other not-for-profit academic research institution that has
entered into a material transfer agreement with Incyte pursuant to Section 3.7,
who is performing collaborative research with Incyte involving use of a
Designated Drug Target, Mutant Mouse or Progeny.
1
3
1.2 "Affiliate" means any corporation, company, partnership, joint
venture and/or firm that controls, is controlled by or is under common control
with a party to this Agreement. For purposes hereof, "control" means (i) in the
case of corporate entities, direct or indirect ownership more than fifty percent
(50%) of the stock or shares entitled to vote for the election of directors; and
(ii) in the case of non-corporate entities, direct or indirect ownership of more
than fifty percent (50%) of the equity interest with the power to direct the
management and policies of such non-corporate entities. [**]
1.3 "Collaboration Term" means the period described in Section 12.1.1.
1.4 "Commercialization Field" means the treatment and prevention of
human diseases and conditions.
1.5 "Confidential Information" means any information and data received
by a party (the "Receiving Party") from the other party or its Affiliates (the
"Disclosing Party") in connection with this Agreement (which, in the case of
Incyte as the Receiving Party, shall include without limitation the LexVision
and OmniBank Databases and all information contained therein and all
documentation related thereto; and which, in the case of Lexicon as the
Receiving Party, shall include without limitation any information and data
relating to Incyte's research and development efforts using the LexVision and
OmniBank Databases, a Mutant Mouse, Progeny or any human ortholog of a mouse
gene contained in the OmniBank Database and discovered by Incyte, and any
research, testing, clinical, regulatory, marketing or other scientific or
business information, plans, or data pertaining to any Product of Incyte).
Notwithstanding the foregoing, Confidential Information shall not include any
part of such information or data that:
(a) is or becomes part of the public domain other than by
unauthorized acts of the Receiving Party, its Affiliates or Corporate
Partners;
(b) can be shown by written documents to have been already in
the possession of the Receiving Party or its Affiliates or its
Corporate Partners prior to disclosure under this Agreement, provided
such Confidential Information was not obtained directly or indirectly
from the Disclosing Party pursuant to a confidentiality agreement;
(c) can be shown by written documents to have been disclosed
to the Receiving Party or its Affiliates or Corporate Partners by a
Third Party, provided such Confidential Information was not obtained
directly or indirectly from the Disclosing Party pursuant to a
confidentiality agreement; or
(d) can be shown by written documents to have been
independently developed by the Receiving Party or its Affiliates or its
Corporate Partners without use of, or access to, Confidential
Information of the Disclosing Party.
Specific Confidential Information of a Disclosing Party shall not be deemed to
come under the foregoing exceptions merely because it is embraced by more
general information that is or becomes part of the public domain, or is known
by, disclosed to or independently developed by the Receiving Party. For example,
coding sequence of a gene disclosed by a Disclosing Party shall not be deemed to
come under the foregoing exceptions merely because genomic DNA
2
4
sequence information relating to such gene is or becomes part of the public
domain, or is known by, disclosed to or independently developed by the Receiving
Party, unless that genomic DNA sequence information has been specifically and
materially established as exon region(s) via standard molecular biology
laboratory techniques.
1.6 "Corporate Partner" means any Third Party, other than an Academic
Collaborator, which enters into an agreement with Incyte or its Affiliates
involving the grant to such Third Party of rights for the development,
commercialization and/or marketing of a Product, and which, if Incyte has
transferred a Designated Drug Target, Mutant Mouse or Progeny to such Third
Party, has entered into a material transfer agreement with Incyte pursuant to
Section 3.7.
1.7 "Cre-Lox Mouse" means any mouse cell or mouse containing a Selected
Mutation and which (i) has one or more lox sites in its genome and (ii) contains
DNA capable of expressing a Cre recombinase protein, and which is made or
produced by Lexicon and delivered to Incyte.
1.8 "Cre-Lox Patent Rights" means the United States and foreign patents
and patent applications listed on Exhibit 1.8, any continuation-in-part,
continuation or divisional applications thereof, any patent granted on any
aforesaid patent application and any extension, revival, re-examination or
reissue of any of such patent, and any continuations, continuations-in-part,
divisionals, reissues, extensions or foreign counterparts of any of the
foregoing, which Lexicon has the right to sublicense hereunder. The terms "Cre"
and "lox" (also referred to as "loxP") have the meanings as described and
embodied by the Cre-Lox Patent Rights.
1.9 "Cre-Lox Technology" means all the inventions described, embodied
by and claimed in the Cre-Lox Patent Rights.
1.10 "Cre Mouse" means any mouse cell or mouse (i) having no lox sites
in its genome and (ii) containing DNA capable of expressing a Cre recombinase
protein.
1.11 "Designated Drug Target" means any Drug Target which (i) is
selected for research and development by Incyte in accordance with the terms and
conditions of this Agreement and (ii) is or has been Used By Incyte (as
hereinafter defined) during the Collaboration Term.
1.12 "Disclosing Party" has the meaning set forth in Section 1.5
hereof.
1.13 "DPC" means DuPont Pharmaceuticals Company.
1.14 "Drug Target" means [**].
1.15 "Effective Date" means the date specified in the initial paragraph
of this Agreement.
1.16 "Event of Default" means an event described in Section 12.3
hereof.
1.17 "First Commercial Sale" means the first sale for use or
consumption by the general public of a Product in a country after all required
marketing and pricing or pricing
3
5
reimbursement approvals to be granted by the governing health authority of such
country have been obtained. For the avoidance of doubt, First Commercial Sale
shall not include the sale of any Product for use in clinical trials or for
compassionate use prior to the approval of an NDA.
1.18 "Homologous Recombination" means a method of making a mouse
containing a Selected Mutation in a particular portion of a gene using standard
homologous recombination techniques.
1.19 "Incyte Know-How" means [**].
1.20 "Incyte Patent Rights" means [**].
1.21 "Incyte Proprietary Program" means [**].
1.22 "Incyte Database Information" means [**].
1.23 "IND" means an Investigational New Drug application filed with the
U.S. Food and Drug Administration or a similar application for the clinical
testing of a Product in human subjects filed with a foreign regulatory
authority.
1.24 "Invention" means any new and useful composition of matter,
process, product by process, machine or manufacture, including without
limitation, software or an arrangement or collection of data, or any new and
useful improvement thereof, whether or not patentable, which has been or is
discovered, conceived, developed or first reduced to practice by employees or
others acting on behalf of Lexicon or its Affiliates (either solely or jointly
with others), or by employees or others acting on behalf of Incyte or its
Affiliates (either solely or jointly with others), through [**].
1.25 "Joint Invention" means any new and useful composition of matter,
process, product by process, machine or manufacture, including without
limitation, software or an arrangement or collection of data, or any new and
useful improvement thereof, whether or not patentable, hereafter discovered,
conceived, made, developed or reduced to practice jointly by employees or others
acting on behalf of Incyte or its Affiliates, together with employees or others
acting on behalf of Lexicon or its Affiliates, through [**].
1.26 "Joint Patent Rights" means (i) any United States and foreign
patent applications, including without limitation provisional patent
applications, hereafter owned, in whole or in part, by Lexicon or Incyte or
having legal force in any country, which claim a Joint Invention, (ii) any
United States patents and foreign patents issuing from such patent applications
and (iii) any substitutions, renewals, continuations, continuations-in-part,
divisionals, reissues, reexaminations or extensions of any of the foregoing.
1.27 "Lexicon Know-How" means all inventions (including Inventions
other than Joint Inventions), discoveries, improvements, know-how, technical
information, data or other technology comprised within or otherwise relating to
the Lexicon Technology that [**], all to the extent and only to the extent that
Lexicon has the right to grant licenses, immunities or other rights to Incyte
hereunder; provided, however, that the Lexicon Know-How excludes the Lexicon
4
6
Patent Rights and any Inventions, discoveries, improvements, know-how, technical
information, data or other technology discovered, conceived, developed or first
reduced to practice under a Lexicon Proprietary Program.
1.28 "Lexicon Patent Rights" means (i) the United States and foreign
patents owned by or licensed (with rights to sublicense) to Lexicon which claim
a composition, method, or process relating to the Lexicon Technology, (ii) the
United States and foreign patent applications, including without limitation
provisional patent applications, heretofore or hereafter filed by Lexicon or
having legal force in any country, which claim a composition, method, or process
relating to the Lexicon Technology, (iii) any United States patents and foreign
patents issuing from such patent applications and (iv) any substitutions,
renewals, continuations, continuations-in-part, divisionals, reissues,
reexaminations or extensions of any of the foregoing, in each case to the extent
(and only to the extent) such patents and patent applications claim [**];
provided that the Lexicon Patent Rights exclude any Joint Patent Rights, the
Cre-Lox Patent Rights and the claims of any patent or patent application filed
by Lexicon directed to Inventions discovered, conceived, developed or first
reduced to practice under a Lexicon Proprietary Program.
1.29 "Lexicon Proprietary Program" means [**].
1.30 "Lexicon Technology" means [**].
1.31 "LexVision Database" means Lexicon's proprietary database
comprising phenotypic data and associated information, as more fully described
in Exhibit 1.31 hereto, and as may be supplemented from time to time as set
forth herein.
1.32 "Lox Mutant Mouse" means a mouse cell or mouse containing a
Selected Mutation (i) having one or more lox sites in its genome and (ii) not
containing DNA capable of expressing a Cre recombinase protein, and which is
made or produced by Lexicon using either the OmniBank Method or Homologous
Recombination and delivered to Incyte.
1.33 "Major Market" means the United States, the European Union (under
the centralized process or any other process), Germany, the United Kingdom,
France, Italy, Spain or Japan.
1.34 "Mutant Mouse" means collectively a Cre Mouse, a Cre-Lox Mouse, a
Lox Mutant Mouse, or a Non-Cre-Lox Mutant Mouse having a Selected Mutation that
was made or produced by Lexicon and delivered to Incyte pursuant to Section 5.2.
A "line of Mutant Mice" means Mutant Mice having the same Selected Mutation. For
purposes of this Agreement, Mutant Mouse shall exclude any mouse cell or mouse
made by Lexicon under the Therapeutic Protein Alliance Agreement between Lexicon
and Incyte of even date herewith.
1.35 "NDA" means a New Drug Application filed with the U.S. Food and
Drug Administration or a similar application for marketing approval of a Product
filed with a foreign regulatory authority.
1.36 "Net Sales" means, with respect to a Product, the gross amount
invoiced by Incyte, its Affiliates or Corporate Partners for sales of such
Product to a Third Party, less:
5
7
(a) trade, quantity and cash discounts actually allowed;
(b) discounts, refunds, rebates, chargebacks, retroactive
price adjustments, billing errors and any other allowances (including,
without limitation, government-mandated and managed health
care-negotiated rebates) actually granted which effectively reduce the
net selling price;
(c) product returns credits and allowances actually granted;
(d) any tax imposed on the production, sale, delivery or use
of the product (excluding federal, state or local taxes based on
income);
(e) freight, postage, shipping, customs duties, excises,
tariffs, surcharges, other governmental charges (excluding federal,
state or local taxes based on income) and insurance charges actually
allowed or paid for delivery of Products;
(f) payments or rebates paid with respect to such Product in
connection with state or federal Medicare, Medicaid or similar programs
in the United States or in connection with similar programs in other
countries in which there are sales; and
(g) adjustments for bad debts.
Such amounts shall be determined from the books and records of Incyte, its
Affiliates or Corporate Partners, as the case may be, maintained in accordance
with the generally accepted accounting principles, consistently applied.
In the event the Product is sold as part of a Combination Product (as
defined below), the Net Sales from the Combination Product, for the purposes of
determining royalty payments, will be determined by multiplying the Net Sales of
the Combination Product by the fraction, A/A+B where A is the average sale price
of the Product when sold separately in finished form and B is the average sale
price of the other active compounds or ingredients in the Combination Product
sold separately in finished form.
In the event that the average sale price of the Product can be
determined but the average sale price of the other active compounds or
ingredients cannot be determined, Net Sales for purposes of determining royalty
payments will be calculated by multiplying the Net Sales of the Combination
Product by the fraction C/C+D where C is the selling party's average sales price
of the Product and D is the difference between the average selling price of the
Combination Product and the average selling price of the Product. If the average
sale price of the other active compounds or ingredients can be determined but
the average price of the Product cannot be determined, Net Sales for purposes of
determining royalty payments will be calculated by multiplying the Net Sales of
the Combination Product by the following formula: one minus C/C+D where C is the
average selling price of the other product(s) and D is the difference between
the average selling price of the Combination Product and the average selling
price of the other active compounds or ingredients.
6
8
In the event that the average sales price of both the Product and the
other active compounds or ingredients in the Combination Product cannot be
determined, the Net Sales of the Product shall be negotiated in good faith by
the parties.
The Net Sales price for a Combination Product in a given country will
be calculated once each calendar year and such price will be used during all
applicable royalty reporting periods for the entire calendar year for such
country, absent extraordinary conditions or events. When determining the average
sale price of a Product or the other active compounds or ingredients in the
Combination Product, the average sale price will be calculated using data
arising from the twelve (12) months preceding the calculation of the Net Sales
price for the Combination Product. As used above, the term "Combination Product"
means any Product sold in conjunction with any other active component(s)
(whether packaged together or in the same therapeutic formulation).
If Incyte or any of its Affiliates or Corporate Partners sells any
Product to a Third Party which also purchases other products or services from
such seller or any of its Affiliates in a bundled, combination or capitated
transaction (a "Bundled Transaction"), and such seller discounts the sales price
of the Product to a greater degree than such seller or its Affiliates generally
discount the price of its other products to such customer, then the aggregate
amount received with respect to such Bundled Transaction shall be allocated to
Net Sales pursuant to the formula set forth in Exhibit 1.36 hereto. For purposes
of the foregoing, "discounting" includes establishing the list price at lower
than the seller's normal pricing level.
Free samples of Product and the disposition of Product for, or the use
of Product in, pre-clinical or clinical (Phase 1 - 3) trials or other
market-focused (Phase 4) trials in which Product is provided to patients without
any payment shall not result in any Net Sales.
1.37 "Non-Cre-Lox Mutant Mouse" means a mouse cell or mouse containing
a Selected Mutation (i) having no lox sites in its genome and (ii) not
containing DNA capable of expressing a Cre recombinase protein, and which is
made or produced by Lexicon using either the OmniBank Method or Homologous
Recombination and delivered to Incyte.
1.38 "OmniBank Database" means Lexicon's proprietary database
comprising OmniBank Sequence Tags and all associated information, as more fully
described in Exhibit 1.38 hereto, and as may be supplemented from time to time
as set forth herein.
1.39 "OmniBank" or "OmniBank Library" means Lexicon's proprietary
library of embryonic stem cell clones containing gene trap events in particular
mouse genes, which genes are identified by OmniBank Sequence Tags, and which
clones may or may not have lox sites, as more fully described in Exhibit 1.38
hereto.
1.40 "OmniBank Method" means the method of making or developing a mouse
containing a Selected Mutation using gene trap insertion techniques with
embryonic stem cells retrieved from the OmniBank Library.
1.41 "OmniBank Sequence Tag" or "OST" means any DNA sequence that is
derived from a mouse gene using gene trap insertion techniques and contained in
the OmniBank Database.
7
9
1.42 "Phase 3 Trial" means a pivotal human clinical trial in any
country the results of which could be used to establish safety and efficacy of a
Product as a basis for an NDA or that would otherwise satisfy the requirements
of 21 CFR 312.21(c) or its foreign equivalent. For purposes of this Agreement,
"commencement of a Phase 3 Trial" for a Product shall mean the introduction of
such Product into a human patient in a Phase 3 Trial.
1.43 "Product" means any Small Molecule Drug product or Small Molecule
Drug product candidate for the treatment or prevention of any human disease or
condition which [**]. Without limiting the foregoing, a Product shall include
any Small Molecule Drug product or product candidate for the treatment or
prevention of any human disease or condition which [**].
1.44 "Product Patent Rights" means (i) the United States and foreign
patent applications, hereafter filed by Incyte, its Affiliates, Academic
Collaborators or Corporate Partners or having legal force in any country, which
claim a composition, method, or process relating to a Product, (ii) any United
States patents and foreign patents issuing from such patent applications and
(iii) any substitutions, renewals, continuations, continuations-in-part,
divisionals, reissues, reexaminations or extensions of any of the foregoing.
1.45 "Progeny" means mice, including successive generations thereof,
that are produced or developed by Incyte, its Affiliates, Academic Collaborators
or Corporate Partners by breeding a Mutant Mouse with any other mouse
(including, without limitation, any other Mutant Mouse); provided that Progeny
shall not include any mouse that does not contain at least one copy of an allele
carrying a Selected Mutation, or nucleotide sequence derived or descended from
an OmniBank vector, stably integrated into its genome.
1.46 "Project Coordinator" has the meaning specified in Section 2.1
hereof.
1.47 "Receiving Party" has the meaning set forth in Section 1.5 hereof.
1.48 "Research Field" means use by Incyte, its Affiliates, Academic
Collaborators and/or Corporate Partners, at the internal research facilities of
Incyte, its Affiliates, Academic Collaborators and Corporate Partners, for
research directed toward the discovery, identification, selection, and
characterization of Products. The Research Field shall specifically exclude (i)
the clinical development, marketing, sale, license or commercialization of any
Product, which activities shall require a license in the Commercialization
Field, and (ii) the development, manufacture, use, lease, sale (or other
transfer for consideration) or importation of any product for sale (or lease or
other transfer of a product for consideration) wherein the manufacture, use,
sale or importation of such product would infringe a Valid Claim of the Cre-Lox
Patent Rights, including but not limited to wherein the product is manufactured
using a composition or method which would infringe a Valid Claim of the Cre-Lox
Patent Rights.
1.49 "Selected Mutation" means a specific mutation in a particular
portion of a gene of a mouse embryonic stem cell that is created using the
OmniBank Method or Homologous Recombination, which may or may not contain lox
sites.
1.50 "Seek-Target-Validation Project" or "S-T-V Project" means
Lexicon's conduct of a Level 2 or 3 S-T-V analysis pursuant to Section 6.1,
which may include, as applicable, the tests and assays described in Exhibit
1.50.
8
10
1.51 "Small Molecule Drug" means any product or product candidate for
the treatment of any human disease or condition, the active ingredient of which
is a synthetic small molecule, a natural product or a macromolecule; provided,
however, that "Small Molecule Drug" specifically excludes any product or product
candidate which consists of or incorporates as an active ingredient [**].
1.52 "Steering Committee" has the meaning specified in Section 2.1
hereof.
1.53 "Territory" means all countries and jurisdictions throughout the
world.
1.54 "Third Party" means any person or entity other than Lexicon or
Incyte and their respective Affiliates.
1.55 "Use by Incyte" or "Used by Incyte" means any of the following:
(a) any use by Incyte or any of its Affiliates of (i) a Drug
Target, which Drug Target or the use thereof is covered by a Valid
Claim of the Lexicon Patent Rights at the time of such use, or (ii)
data or other information from the LexVision or OmniBank Database
relating to a Drug Target which is included in the Lexicon Know-How at
the time of such use, in any such case which use meets any or all of
the following criteria:
[**]
1.56 "Valid Claim" means either (i) a claim of an issued and unexpired
patent which has not been held permanently revoked, unenforceable or invalid by
a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal and that is not
admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise, or (ii) a claim of a pending patent application that [**]and that has
not been abandoned or finally rejected without the possibility of appeal or
refiling.
ARTICLE 2. STEERING COMMITTEE
2.1 Members of Steering Committee; Project Coordinators. The
parties shall establish a steering committee (the "Steering Committee"), which
shall comprise three representatives designated by each party (or such other
number as the parties may agree). The initial members of the Steering Committee
are set forth on Exhibit 2.1. Members of the Steering Committee may be
represented at any meeting by a designee who is appointed by such member for
such meeting and who has authority to act on behalf of such member. The
chairperson of the Steering Committee shall be designated annually on an
alternating basis between the parties. The initial chairperson shall be selected
by Incyte and is designated on Exhibit 2.1. The party not designating the
chairperson shall designate one of its representative members as secretary to
the Steering Committee for such year. Each party shall designate an individual
(a "Project Coordinator"), who may, but need not, be a member of the Steering
Committee to coordinate, on its behalf, the day-to-day interaction of and
communication between the parties under this Agreement. Each Project Coordinator
shall possess the education, training and experience necessary to make him or
her reasonably technically qualified to serve as a Project Coordinator.
9
11
The initial Project Coordinators are set forth on Exhibit 2.1. Each party shall
be free to replace its representative members of the Steering Committee and its
Project Coordinator with new appointees who have authority to act on behalf of
such party, on notice to the other party.
2.2 Responsibilities of Steering Committee. The Steering Committee
shall be responsible for overseeing and directing the parties' interaction and
performance of their respective obligations under this Agreement. Without
limiting the generality of the foregoing, its duties shall include:
(a) evaluating and modifying, from time to time, the tests and
analytical methods to be used in Level 2 and 3 S-T-V Projects conducted
by Lexicon under this Agreement;
(b) prioritizing and reviewing Lexicon's efforts to develop
and supply Mutant Mice pursuant to Article 5;
(c) establishing criteria and strategies for seeking patent
protection for Joint Inventions;
(d) providing for the exchange of information between the
parties; and
(e) addressing issues and resolving differences that may arise
between the parties.
2.3 Meetings of Steering Committee. The Steering Committee shall
meet at least once every calendar quarter, and more frequently as the parties
deem appropriate, on such dates and at such times as the parties shall agree, on
ten (10) days' written notice to the other party unless such notice is waived by
the parties. The first meeting of the Steering Committee shall take place within
thirty (30) days after the Effective Date, at Lexicon's facility in The
Woodlands, Texas. The Steering Committee may convene or be polled or consulted
from time to time by means of telecommunications, videoconferences or
correspondence, as deemed necessary or appropriate by the parties. To the extent
that meetings are held in person, they shall alternate between the offices of
the parties unless the parties otherwise agree. The chairperson shall be
responsible for sending notices of meetings to all members.
2.4 Decisions.
2.4.1 Quorum; Voting. A quorum for a meeting of the Steering
Committee shall require the presence of at least one Lexicon member (or
designee) and at least one Incyte member (or designee) in person or by
telephone. All decisions made or actions taken by the Steering
Committee shall be made unanimously by its members, with the Lexicon
members cumulatively having one vote and the Incyte members
cumulatively having one vote.
2.4.2 Dispute Resolution. In the event that unanimity cannot
be reached by the Steering Committee with respect to a matter that is a
subject of its decision-making authority, then the matter shall be
referred for further review and resolution to the Chief Executive
Officer of Incyte, or such other similar position designated by Incyte
from time
10
12
to time, and the Chief Executive Officer of Lexicon, or such other
similar position designated by Lexicon from time to time. The
designated officers of each party shall use reasonable efforts to
resolve the matter within [**] after the matter is referred to them. If
the designated officers cannot resolve any matter described in Section
2.2 within such [**] period, the matter shall be decided by the
designated officer of Lexicon in good faith, taking into account the
reasonable commercial interests of Incyte and the express provisions of
this Agreement.
2.5 Minutes. Within fifteen (15) days after each Steering Committee
meeting, the secretary of the Steering Committee shall prepare and distribute
minutes of the meeting, which shall provide a description in reasonable detail
of the discussions had at the meeting and a list of any actions, decisions or
determinations approved by the Steering Committee. The secretary shall be
responsible for circulation of all draft and final minutes. Draft minutes shall
be first circulated to the chairperson, edited by the chairperson and then
circulated in final draft form to all members of the Steering Committee
sufficiently in advance of the next meeting to allow adequate review and comment
prior to the meeting. Minutes shall be approved or disapproved, and revised as
necessary, at the next meeting. Final minutes shall be distributed to the
members of the Steering Committee.
2.6 Term. The Steering Committee shall exist until the termination or
expiration of the Collaboration Term and for such longer period as necessary to
perform the responsibilities assigned to it under this Agreement.
2.7 Expenses. Each party shall be responsible for all travel and
related costs for its representatives to attend meetings of, and otherwise
participate on, the Steering Committee.
ARTICLE 3. GRANTS OF RIGHTS
3.1 Grant of Rights and Licenses by Lexicon to Incyte.
3.1.1 Non-Exclusive Grant of Access to LexVision and OmniBank
Databases. Subject to the terms of this Agreement, Lexicon hereby
grants to Incyte and its Affiliates, during the Collaboration Term, the
non-exclusive right under the Lexicon Patent Rights and Lexicon
Know-How of access, without the right to permit Third Parties any right
of access, to the LexVision and OmniBank Databases for use in the
Research Field only. Incyte and its Affiliates may make copies of
information contained in the LexVision and OmniBank Databases only to
the extent reasonably necessary to exercise Incyte's rights under this
Agreement, and Incyte agrees to establish, and to cause its Affiliates
to establish, reasonable security measures to prevent copies of the
information contained in the LexVision and OmniBank Databases from
being made available to Third Parties (except as provided in Section
3.7), all to the same extent required for the protection of Lexicon's
other Confidential Information under Section 9.1.
3.1.2 Non-Exclusive Research License Grant under the Lexicon
Patent Rights and Lexicon Know-How for Drug Discovery. At any time
during the Collaboration Term, Incyte may, at its option, designate a
Drug Target as a Designated Drug Target by
11
13
providing written notice of such designation to Lexicon; provided that
Incyte shall be obligated to designate each Drug Target Used by Incyte
as a Designated Drug Target promptly following the date such Drug
Target is first Used by Incyte. Subject to the terms of this Agreement,
Lexicon hereby grants to Incyte and its Affiliates, within the
Territory, a non-exclusive right and license (without any right to
sublicense except as specifically provided herein) under the Lexicon
Patent Rights and Lexicon Know-How with respect to Designated Drug
Targets solely in the Research Field. Lexicon hereby grants Incyte and
its Affiliates the limited right to grant sublicenses to Corporate
Partners and Academic Collaborators under the right and license granted
by Lexicon pursuant to this Section 3.1.2, on a Designated Drug
Target-by-Designated Drug Target basis, solely to accomplish the
purposes of such Corporate Partner's or Academic Collaborator's
collaboration with Incyte or its Affiliates, as provided in Section
3.7.
3.1.3 Non-Exclusive Commercial License Grant under the Lexicon
Patent Rights and Lexicon Know-How for Small Molecule Drugs. Subject to
the terms of this Agreement, Lexicon hereby grants to Incyte and its
Affiliates, within the Territory, a non-exclusive right and license
(without the right to sublicense except as specifically provided
herein) under the Lexicon Patent Rights and Lexicon Know-How with
respect to Designated Drug Targets to discover, develop, make, have
made, import, use, have used, offer for sale, sell and have sold Small
Molecule Drugs in the Commercialization Field. Lexicon hereby grants
Incyte and its Affiliates the limited right to grant sublicenses to
Corporate Partners and Academic Collaborators under the right and
license granted by Lexicon pursuant to this Section 3.1.3, on a
Designated Drug Target-by-Designated Drug Target basis, solely to
accomplish the purposes of such Corporate Partner's or Academic
Collaborator's collaboration with Incyte or its Affiliates, as provided
in Section 3.7.
3.1.4 Non-Exclusive Research License Grant under the Lexicon
Patent Rights and Lexicon Know-How to Mutant Mice and Progeny. Subject
to the terms of this Agreement, Lexicon hereby grants to Incyte and its
Affiliates within the Territory, a non-exclusive right and license
under the Lexicon Patent Rights and Lexicon Know-How to use, breed,
cross-breed and have bred and cross-bred Mutant Mice and Progeny for
use in the Research Field only. Except as provided in Section 3.7,
Incyte agrees to use the Mutant Mice and Progeny solely for Research
Field purposes of Incyte and its Affiliates in accordance with the
terms and conditions of this Agreement, and not to use the Mutant Mice
or Progeny for any purposes for Third Parties, or to transfer, license
the use of or make available to Third Parties Mutant Mice or Progeny.
Lexicon hereby grants Incyte and its Affiliates the limited right to
grant sublicenses to Corporate Partners and Academic Collaborators
under the right and license granted by Lexicon pursuant to this Section
3.1.4, on a Designated Drug Target-by-Designated Drug Target basis,
solely to accomplish the purposes of such Corporate Partner's or
Academic Collaborator's collaboration with Incyte or its Affiliates, as
provided in Section 3.7.
3.1.5 Non-Exclusive Research License Grant under the Cre-Lox
Technology to Lox Mutant Mice, Cre-Lox Mice, Cre Mice and Progeny.
3.1.5.1 Subject to the terms of this Agreement,
Lexicon hereby grants to Incyte and its Affiliates the
non-transferable (except to Academic Collaborators
12
14
and Corporate Partners as provided in Section 3.1.5.2),
non-exclusive right under the Cre-Lox Technology to use, breed
and cross-breed Lox Mutant Mice solely in the Research Field;
provided however, that Incyte and its Affiliates shall not
manipulate the genetic information at any lox site of a Lox
Mutant Mouse by using the Cre-Lox Technology (including
without limitation cross-breeding a Lox Mutant Mouse with a
Cre Mouse) or otherwise further practice under the Cre-Lox
Patents, without first obtaining a license from DPC.
3.1.5.2 Incyte and its Affiliates shall not transfer
any Lox Mutant Mice or any Progeny or material in any way
derived from such Lox Mutant Mice to any Third Party, except
as follows: Incyte may transfer Lox Mutant Mice (or any
Progeny or material in any way derived from such Lox Mutant
Mice) to Academic Collaborators and Corporate Partners,
provided that each such Academic Collaborator or Corporate
Partner has first entered into a Material Transfer Agreement
with Incyte substantially in the form and containing the terms
as set forth in Exhibit 3.7-B hereto.
3.1.5.3 No right is granted to Incyte or its
Affiliates to sell (or lease or otherwise transfer for
consideration) or develop or manufacture for sale (or lease or
other transfer for consideration) any product, the
manufacture, use, sale or importation of which would infringe
a Valid Claim of the Cre-Lox Patents, including but not
limited to any product which is manufactured using a
composition or method which would infringe a Valid Claim of
the Cre-Lox Patents.
3.1.5.4 Subject to the restricted non-exclusive
rights granted to Incyte, Lexicon (and its licensors, as
applicable) shall retain all rights under the Cre-Lox
Technology to Lox Mutant Mice (and any Progeny or material in
any way derived from such Lox Mutant Mice).
13
15
3.2 Use of LexVision Data in Support of Incyte Patents. Subject to the
terms of this Agreement, Lexicon hereby grants to Incyte and its Affiliates,
within the Territory, a non-exclusive right and license (without any right to
sublicense) under the Lexicon Patent Rights and Lexicon Know-How to use data or
other information from the LexVision Database relating to Drug Targets to
support the prosecution or issuance of claims of the Incyte Patent Rights that
(i) claim the composition of matter of a Drug Target and/or (ii) arise solely
from the generation of Incyte Database Information and claim the use of a Drug
Target with respect to human therapeutic and diagnostic products (and any
substitutions, renewals, continuations, continuations-in-part, divisionals,
reissues, reexaminations or extensions of any of the foregoing). The use of such
information in support of the Incyte Patent Rights will not result in such
Incyte Patent Rights becoming Joint Patent Rights. Lexicon shall execute such
documents and take such additional steps as Incyte may reasonably request to
enable Incyte to exercise its rights under this Section 3.2.
3.3 Reservation of Rights. Notwithstanding the rights granted to Incyte
under this Article 3:
3.3.1 Lexicon at all times reserves (i) the right to use and
to permit others to access and use the LexVision and OmniBank
Databases, and any information or date contained therein, to discover,
research, develop, make, have made, import, use, have used, offer for
sale, sell and have sold products, including the right to grant
licenses with respect to any applicable intellectual property rights
for such purpose; (ii) the right to use and to permit others to use,
breed and have bred Mutant Mice and successive generations thereof to
discover, research, develop, make, have made, import, use, have used,
offer for sale, sell and have sold products, including the right to
grant licenses with respect to any applicable intellectual property
rights for such purpose; and (iii) its rights under the Lexicon Patent
Rights and Lexicon Know-How to all embryonic stem cell clones and other
biological materials contained in the OmniBank Library.
3.3.2 Lexicon reserves the right under the Lexicon Patent
Rights and Lexicon Know-How (i) to discover, research, develop, make,
have made, import, use, have used, offer for sale, sell and have sold
Drug Targets and Products, and (ii) to grant licenses to Third Parties
to discover, research, develop, make, have made, import, use, have
used, offer for sale, sell and have sold Drug Targets and Products.
3.4 No Grant of Other Technology or Patent Rights. Except as otherwise
expressly provided in this Agreement, under no circumstances shall a party
hereto, as a result of this Agreement, obtain any ownership interest in or other
right to any technology, know-how, patents, patent applications, gene or genomic
xxxxxxxx xxxx or information, products, or biological materials of the other
party, including items owned, controlled or developed by, or licensed to, the
other party, or transferred by the other party to said party, at any time
pursuant to this Agreement.
14
16
3.5 Grant of Non-Blocking Rights Among Incyte, Lexicon and Reciprocal
Rightsgivers.
3.5.1 Rights to Use the LexVision Database, OmniBank Database
and Mutant Mice.
3.5.1.1 Incyte and its Affiliates shall not assert or
enforce, and shall use good faith efforts to obtain the
written agreement of its Corporate Partners not to assert or
enforce, against Lexicon, its Affiliates or any Reciprocal
Rightsgiver (as defined below) any claims of an issued patent
arising from the use by Incyte, its Affiliates, Academic
Collaborators or Corporate Partners of the LexVision or
OmniBank Databases or any information therein, or arising from
the use by Incyte, its Affiliates, Academic Collaborators or
Corporate Partners of an OST, a Mutant Mouse or Progeny,
including, without limitation, any claims of an issued patent
to an Invention made by Incyte, its Affiliates, Academic
Collaborators or Corporate Partners, to the extent, but only
to the extent, any such assertion or enforcement would, absent
a license from Incyte, prevent Lexicon, any of its Affiliates
or any Reciprocal Rightsgiver from using (and/or, in the case
of Lexicon and its Affiliates, permitting others to use), for
research purposes only (including, without limitation,
research directed toward the discovery, identification,
selection, or characterization of human therapeutic and
diagnostic products), (i) the LexVision or OmniBank Databases,
any information therein or any OST; (ii) any Mutant Mice or
Progeny or other mice having a Selected Mutation; or (iii) any
embryonic stem cell clones or other biological materials
contained in the OmniBank Library.
3.5.1.2 Lexicon and its Affiliates shall not assert
or enforce, and shall use good faith efforts to obtain the
written agreement of its corporate partners not to assert or
enforce, against Incyte or its Affiliates any claims of an
issued patent arising from the use by Lexicon, its Affiliates,
academic collaborators or corporate partners of the LexVision
or OmniBank Databases or any information therein, or arising
from the use by Lexicon, its Affiliates, academic
collaborators or corporate partners of an OST, a Mutant Mouse
or Progeny, including, without limitation, any claims of an
issued patent to an Invention made by Lexicon, its Affiliates,
academic collaborators or corporate partners, to the extent,
but only to the extent, any such assertion or enforcement
would, absent a license from Lexicon, prevent Incyte or any of
its Affiliates from using, for research purposes only
(including, without limitation, research directed toward the
discovery, identification, selection, or characterization of
human therapeutic and diagnostic products), (i) the LexVision
or OmniBank Databases, any information therein or any OST;
(ii) any Mutant Mice or Progeny or other mice having a
Selected Mutation; or (iii) any embryonic stem cell clones or
other biological materials contained in the OmniBank Library.
3.5.2 "Reciprocal Rightsgiver," for purposes of Section
3.5.1, respectively, means a Third Party licensee under the Lexicon
Patent Rights and/or Lexicon Know-How which has agreed, in writing, to
terms and conditions concerning the subject matter of
15
17
such section that are at least as advantageous to Incyte and Lexicon
and their respective Affiliates (including, without limitation, with
respect to assignment, as provided below) in the Research Field or with
respect to Products in the Commercialization Field, respectively, as
the terms and conditions under Section 3.5.1, as applicable, are to
such Third Party. Furthermore, except to the extent expressly provided
herein, neither Incyte nor Lexicon nor any Reciprocal Rightsgiver shall
have the right to assign, transfer or otherwise dispose of (with or
without consideration), in whole or in part, any of its rights under
this Section 3.5 (or, in the case of Incyte, under the equivalent
provisions of Lexicon's agreements with Reciprocal Rightsgivers) except
in connection with a merger, consolidation or sale with or to any
unrelated Third Party of such portion of Incyte's, Lexicon's or such
Reciprocal Rightsgiver's assets that include such rights; that is to
say, Incyte's, Lexicon's or such Reciprocal Rightsgiver's rights under
this Section 3.5 (or, in the case of Incyte, under the equivalent
provisions of Lexicon's agreements with Reciprocal Rightsgivers) shall
be assumed by such person's successor in interest in any such
transaction and shall not be transferred separate from all or
substantially all of its other business assets. Any purported
assignment of rights under this Section 3.5 in violation of the
preceding sentence shall be void.
3.5.4 Incyte, Lexicon and each Reciprocal Rightsgiver shall
provide Lexicon's Project Coordinator with a copy of any patent
application that such person reasonably believes will be implicated
under this Section 3.5, promptly after such application is first
published anywhere in the Territory. Lexicon's Project Coordinator
shall distribute copies of such patent application to Incyte, Lexicon
and each Reciprocal Rightsgiver (other than the person which filed the
application) and shall indicate the applicability of Section 3.5
thereto. The parties acknowledge and agree that initial determination
of whether a patent application is implicated under this Section 3.5
may be difficult. Therefore, no person shall be held liable for failure
to comply with this Section 3.5.4 (or under the equivalent provisions
of Lexicon's agreements with Reciprocal Rightsgivers) with regard to
any particular patent application, so long as such failure was
reasonable and in good faith and is promptly rectified when realized.
3.5.5 Lexicon shall use good faith efforts to obtain from each
Third Party that becomes a subscriber to the LexVision Database during
the Collaboration Term agreements in favor of Reciprocal Rightsgivers
(including Incyte) on substantially the same terms as those set forth
in this Section 3.5, so that such Third Party subscriber becomes a
Reciprocal Rightsgiver. To the extent permitted, Lexicon shall
periodically disclose to the Steering Committee the identity of any
such Reciprocal Rightsgivers and the terms and conditions agreed to by
such Reciprocal Rightsgivers under which Incyte receives rights
reciprocal to those specified in this Section 3.5.
3.5.6 Incyte and each Reciprocal Rightsgiver shall have the
right to enforce the provisions of this Section 3.5 or the equivalent
provisions of Lexicon's agreements with such Reciprocal Rightsgiver, as
the case may be, as if each were a party to the agreements containing
such provisions.
3.6 Non-Blocking License under Incyte Patents Supported by LexVision
Data.
16
18
3.6.1 Subject to the terms of this Agreement, Incyte hereby
grants to Lexicon and its Affiliates, within the Territory, a
non-exclusive right and license (without the right to sublicense except
as specifically provided herein) to research, develop, manufacture,
have manufactured and sell "Drug Products" (as hereinafter defined)
under claims of the Incyte Patent Rights (and any substitutions,
renewals, continuations, continuations-in-part, divisionals, reissues,
reexaminations or extensions of any of the foregoing) that (a) (i)
claim the composition of matter of a Drug Target and/or (ii) arise
solely from the generation of Incyte Database Information and claim the
use of a Drug Target with respect to Drug Products, and (b) for which
data or other information from the LexVision Database relating to such
Drug Target was used to support the prosecution or issuance of such
patent; provided that such right and license shall not extend to claims
of any Incyte patent or patent application to an invention or discovery
made in an Incyte Proprietary Program. Lexicon may grant sublicenses to
Third Parties under the right and license granted to Lexicon under this
Section 3.6.1 to the extent, and only to the extent, that Lexicon
grants such Third Party (i) a corresponding license or sublicense of
rights to a given Drug Product discovered, researched and under bona
fide commercial development (at least through the stage of the
demonstration of pre-clinical efficacy in animal studies) by Lexicon
and (ii) the license or sublicense of patent rights pertaining thereto
owned by, licensed to or controlled by Lexicon. For purposes of this
Section 3.6.1, "Drug Products" shall mean [**].
3.6.2 Incyte shall provide Lexicon's Project Coordinator with
a copy of any Incyte patent or patent application (and any United
States patents and foreign patents issuing from such patent
applications and any substitutions, renewals, continuations,
continuations-in-part, divisionals, reissues, reexaminations or
extensions of any of the foregoing) under which Lexicon holds license
rights pursuant to this Section 3.6, promptly after such application is
first published anywhere in the Territory.
3.7 Sublicenses, Transfers to or Use for the Benefit of Corporate
Partners and Academic Collaborators.
3.7.1 Incyte and its Affiliates shall have the limited right
to grant sublicenses to Corporate Partners and Academic Collaborators
under the Lexicon Patent Rights and Lexicon Know-How in the Research
Field with respect to any Designated Drug Target, on a Designated Drug
Target-by-Designated Drug Target basis, solely to accomplish the
purposes of such Corporate Partner's or Academic Collaborator's
collaboration with Incyte or its Affiliates; provided, however, that
without the prior written consent of Lexicon, no such sublicense under
the Lexicon Patent Rights or Lexicon Know-How with respect to such
Designated Drug Target may be granted to any Third Party in the absence
of (i) a corresponding license or sublicense of rights to a given
Product discovered, researched and under bona fide commercial
development (at least through the stage of the demonstration of
pre-clinical efficacy in animal studies) by Incyte and (ii) the license
or sublicense of patent rights pertaining thereto owned by, licensed to
or controlled by Incyte; and provided, further, that the grant of any
such sublicense shall be consistent with the terms and conditions of
this Agreement and that no such sublicense to a Corporate Partner shall
relieve Incyte of primary responsibility for all payments and royalties
due to Lexicon under Article 7 with respect to Product(s) licensed to
such
17
19
Corporate Partner. Incyte shall obtain the written commitment of any
sublicensee to abide by all applicable terms and conditions of this
Agreement. Promptly upon execution of any permitted sublicense, Incyte
shall provide written notice thereof to Lexicon and evidence reasonably
satisfactory to Lexicon that such sublicense is in compliance with this
Section 3.7.1.
3.7.2 Incyte and its Affiliates shall have the right to
transfer a Mutant Mouse or Progeny to a Corporate Partner or an
Academic Collaborator, provided that such Corporate Partner or Academic
Collaborator shall have entered into a material transfer agreement with
Incyte substantially in the form and containing the terms as set forth
in Exhibit 3.7-A or 3.7-B, whichever is applicable. Within [**] of
entering into any such material transfer agreement, Incyte shall
provide Lexicon with a copy thereof.
3.7.3 Except as provided in Section 3.7.1 above, Incyte shall
have no right to grant any sublicense under its rights under the
Lexicon Patent Rights or Lexicon Know-How. Under no circumstances shall
Incyte provide direct access to the LexVision or OmniBank Database to
any Corporate Partner, Academic Collaborator or other Third Party.
ARTICLE 4. ACCESS TO LEXVISION AND OMNIBANK DATABASES
4.1 Access to the LexVision and OmniBank Databases. Within thirty (30)
days after the Effective Date, Lexicon shall provide Incyte with [**] access,
using [**], to the LexVision and OmniBank Databases in their most current
versions as of the access activation date. Incyte shall access the LexVision and
OmniBank Databases through one or more servers in secure locations at its
principal research facilities in Palo Alto, California, or such alternate
research site as Incyte may designate by written notice to Lexicon; provided,
however, Incyte shall be entitled to access the LexVision and OmniBank Databases
remotely from computers which are part of a Incyte intranet system. [**]. Up to
[**] concurrent Incyte users (and [**] total users) at Incyte's principal
research facilities in Palo Alto, California, or an alternate site designated by
written notice to Lexicon, shall be permitted to access the LexVision and
OmniBank Databases through such servers at any given time. Incyte shall take
reasonable precautions to restrict access to the LexVision and OmniBank
Databases to the scientists and other employees of Incyte and its Affiliates who
have access to Incyte's own proprietary gene databases, including without
limitation all precautions Incyte employs with respect to its own proprietary
gene databases. Incyte shall not provide any Academic Collaborator, Corporate
Partner or other Third Party with direct access to the LexVision or OmniBank
Databases and, except as provided in Section 3.7, shall not disclose any
information contained therein to any Academic Collaborator, Corporate Partner or
other Third Party.
4.2 Updates to the LexVision and OmniBank Databases. During the
Collaboration Term, Lexicon will use commercially reasonable efforts to update
the LexVision and OmniBank Database, [**] at least once every two months, and
Lexicon shall, in all events, make such updates for Incyte at least as
frequently and promptly as Lexicon makes updates available to other subscribers
to the LexVision or OmniBank Databases, as the case may be. Without limiting the
foregoing, Lexicon will use commercially reasonable efforts to include in the
18
20
LexVision Database the phenotypic data from substantially the assays described
on Exhibit 1.28, as may be modified from time to time by Lexicon, for the
following numbers of murine genes upon the following schedule:
Deadline Number of Genes (Total)
-------- -----------------------
[**]
4.3 Support for the LexVision and OmniBank Databases.
4.3.1 During the Collaboration Term, Lexicon will provide
reasonable technical support for the LexVision and OmniBank Databases
during normal business hours (9:00 a.m. to 5:00 p.m. Central time).
Requests for support shall be coordinated by the Project Coordinator
designated by each party.
4.3.2 If the LexVision Database and/or OmniBank Database
malfunctions or for some reason becomes nonoperational, Incyte shall
notify Lexicon within [**] of such occurrence. Lexicon shall respond to
all such notices within [**] of receipt and shall use reasonable
efforts to correct defects in the LexVision Database and/or OmniBank
Database within time frames corresponding to the severity of the
defects, as agreed upon by Lexicon and Incyte.
4.3.3 Both parties shall use all reasonable efforts to
minimize any the downtime of the LexVision Database and OmniBank
Database and shall discuss, in good faith, equitable adjustment of the
parties' respective obligations under this Agreement as a result of any
extraordinary period of downtime.
4.4 Incyte Designation of Genes for Inclusion in LexVision Database.
4.4.1 In each of the first four years of the Collaboration
Term, Incyte will have the right to designate for inclusion in the
LexVision Database up to [**] of the murine genes to be included in the
LexVision Database in the following year pursuant to Section 4.2.
Incyte shall designate such genes by written notice in the form
attached hereto as Exhibit 4.4.1 delivered to Lexicon (i) within [**]
of the Effective Date for the murine genes designated by Incyte for the
following year and (ii) no fewer than [**] prior to each anniversary of
the Effective Date for the murine genes designated by Incyte for each
subsequent year. [**].
4.4.2 [**].
4.4.3 If Incyte does not provide Lexicon with the murine DNA
sequence for the gene for which it desires a Selected Mutation (e.g.,
Incyte provides only a human DNA expressed sequence tag or full-length
coding region for which it desires Lexicon to obtain the murine
homolog), Lexicon will use commercially reasonable efforts in
performing the following activities in the following order: [**].
4.4.4 In the event that Lexicon is unsuccessful in identifying
the murine homolog of a human expressed sequence tag or full-length
coding region provided by
19
21
Incyte pursuant to Section 4.4.3, Lexicon shall, within [**] after
receipt of Incyte's designation of such gene or such failure by
Lexicon, as the case may be, notify Incyte, and Incyte shall thereafter
be entitled, but not required, to designate a replacement gene. Incyte
shall designate any such replacement gene no later than [**] after
receiving such notice from Lexicon.
ARTICLE 5. DEVELOPMENT AND SUPPLY OF MUTANT MICE
5.1 General. Subject to the terms of this Agreement, upon the written
request of Incyte, Lexicon shall develop and deliver Mutant Mice containing a
particular Selected Mutation as may be specifically requested by Incyte.
5.2 Requests for Mutant Mice by Incyte. During each year of the
Collaboration Term, Incyte shall have the option, subject to the terms and
conditions of this Agreement, to request that Lexicon develop and deliver to
Incyte up to [**] lines of Mutant Mice [**].
5.3 Development of Mutant Mice by Lexicon. Following a request by
Incyte that Lexicon develop and deliver a particular line of Mutant Mice,
Lexicon shall provide Incyte with quarterly reports regarding Lexicon's efforts
in developing such Mutant Mouse and shall permit Incyte scientists to confer
with the Lexicon scientists who are developing such lines of Mutant Mice, from
time to time, at mutually convenient times coordinated by the Project
Coordinator for each party. It is understood by the parties that Lox Mutant
Mice, Cre-Lox Mice and Non-Cre-Lox Mutant Mice delivered by Lexicon will be
heterozygous at the Selected Mutation.
5.4 Maintenance of Back-Up Colonies. For a period of [**], Lexicon
shall retain a small back-up colony of approximately two cages of such Mutant
Mice (approximately five mice per cage), for the purpose of replacing mice
shipped to Incyte under this Article 5 which die during or within [**] after
shipment to Incyte hereunder. Thereafter, Lexicon shall [**]. In the event
Incyte requests that Lexicon maintain any such colony for a period of more than
[**], Incyte shall pay Lexicon a storage and maintenance charge of [**] for such
requested line of Mutant Mice for each additional week that Lexicon maintains
such colony at Incyte's request.
5.5 Delivery Terms and Conditions. Incyte shall be responsible for
making shipping arrangements for all Mutant Mice to be shipped to Incyte from
Lexicon. Incyte shall also be responsible for complying with all customs,
regulations, veterinary handling procedures and protocols, and obtaining any and
all permits, forms or permissions that may be required for Incyte to accept
shipment of Mutant Mice from Lexicon. To facilitate timely compliance with such
requirements, a copy of a standard Lexicon mutant mouse shipping and transfer
report is attached in Exhibit 5.5. Lexicon will specify a reputable, experienced
shipping company located in the same metropolitan area as Lexicon with which
Incyte may make arrangements for shipping and delivery of such Mutant Mice.
Lexicon shall ship to Incyte at least one female and one male Mutant Mouse with
the Selected Mutation, each of breeding age (i.e., a "breeding pair"), promptly
following its receipt of payment and written notice that Incyte has completed
the necessary shipping arrangements. Risk of loss with respect to any Mutant
Mice to be transferred under this Section 5.5 shall pass to Incyte upon delivery
thereof to the shipping company designated as specified herein. If Incyte fails
to complete the necessary shipping
20
22
arrangements and provide such notice within [**] after Lexicon's delivery of a
notice pursuant to Section 5.3, Incyte shall pay Lexicon a storage and
maintenance charge of [**] for such requested line of Mutant Mice for each week
thereafter until Lexicon receives notice of the completion of such shipping
arrangements. All out-of-pocket transportation and transfer costs associated
with the transfer and delivery of Mutant Mice from Lexicon to Incyte shall be
paid by Incyte.
5.6 Reasonable Efforts. Lexicon shall use commercially reasonable
efforts to complete the generation of (i) Mutant Mice made by the OmniBank
Method within [**] of the date of Incyte's request, (ii) Lox Mutant Mice and
Non-Cre-Lox Mutant Mice made by Homologous Recombination within [**] of the date
of Incyte's request, and (iii) Cre-Lox Mice made by Homologous Recombination
within [**] of the date of Incyte's request. Incyte recognizes that the
production of Mutant Mice involves a number of technologically complex steps and
that technical obstacles may prevent Lexicon from producing Mutant Mice on the
schedule provided for herein. Lexicon shall immediately notify Incyte of any
such technical obstacle encountered and its analysis of whether the obstacle can
be overcome and the time required to do so. If, after consultation with Incyte,
Lexicon determines that production of such Mutant Mice within the time periods
provided for herein is not feasible using commercially reasonable efforts,
Lexicon may notify Incyte in writing that it is extending the relevant delivery
date to a date that can be accomplished using commercially reasonable efforts;
provided that Incyte may [**].
5.7 No Infringement of Third Party Rights. Lexicon shall not be
obligated to develop, produce or deliver a Mutant Mouse where Lexicon reasonably
believes, with the advice of its counsel and the Steering Committee, that such
action would infringe upon the intellectual property rights of a Third Party. In
such event, the Steering Committee shall adopt an acceptable solution including,
but not limited to, the identification by Incyte of an alternative Mutant Mouse
and, subject to Section 7.4, the production, development and analysis by Lexicon
of non-infringing Mutant Mice. [**].
5.8 [**].
ARTICLE 6. S-T-V PHENOTYPIC ANALYSIS
6.1 Xxxxx 0 xxx Xxxxx 0 X-X-X Projects. Terms for Xxxxx 0 xxx Xxxxx 0
X-X-X Projects shall be negotiated in good faith between the parties on a
target-specific basis. Unless otherwise mutually agreed, the consideration to
Lexicon for the conduct of any Xxxxx 0 xx Xxxxx 0 X-X-X Project shall include
payments for project costs, and, as appropriate, upfront license fees,
milestones and/or royalties on Products developed using data from such S-T-V
Project. Unless otherwise mutually agreed, Incyte and Lexicon exclusively shall
have the right to use the data and results from each Xxxxx 0 xxx Xxxxx 0 X-X-X
Project (and Incyte shall have the right to provide same to any of Incyte's
Corporate Partners and Academic Collaborators in accordance with Section 3.7),
and Incyte shall have a right and license (with the right to sublicense same to
any of Incyte's Corporate Partners and Academic Collaborators in accordance with
Section 3.7) under the Lexicon Patent Rights and Lexicon Know-How to use any
Invention owned by Lexicon under Section 8.1.4 that arises directly from such
analysis.
21
23
6.2 Restrictions on Rights to Disclose Data. Neither party will have
the right to disclose any data, results or Inventions from an S-T-V Project
performed for Incyte under Section 6.1 to any Third Party, except that Incyte
will have the right to disclose such data, results and Inventions to Academic
Collaborators and Corporate Partners who need to know same for purposes of their
collaborations with Incyte; provided that, if independently requested by a Third
Party, Lexicon may conduct independent Xxxxx 0 xxx/xx Xxxxx 0 X-X-X Projects
with respect to the same lines of Mutant Mice for such Third Party (i.e.,
Lexicon may not share the specific data, results or Inventions from the work
done for Incyte in a Xxxxx 0 xxx/xx Xxxxx 0 X-X-X Project, but may disclose data
and results generated from a complete course of work repeated or otherwise
separately conducted for such Third Party).
ARTICLE 7. PAYMENTS
7.1 Access Fees. In consideration of the rights and licenses granted to
Incyte during the Collaboration Term hereunder, Incyte agrees to pay Lexicon,
during the Collaboration Term, annual access fees (each, an "Access Fee") in the
amount of [**], payable as provided herein. The Access Fee for the first year of
the Collaboration Term will be payable [**], and will be payable [**] for
subsequent years of the Collaboration Term; provided, however, that, in the
event that either party terminates the Collaboration Term at the third
anniversary of the Effective Date in accordance with Section 12.1.2, Incyte
shall not be obliged to pay the Access Fees for the last two years of the
Collaboration Term.
7.2 Milestone Payments Payable by Incyte.
7.2.1 Incyte shall pay Lexicon the following milestone
payments for each Product:
Milestone Amount of Milestone Payment
--------- ---------------------------
[**]
7.2.2 Incyte shall promptly notify Lexicon of the first
occurrence of any milestone with respect to each Product, and milestone
payments shall be made within [**] days after such occurrence.
Milestone payments shall be made only once with respect to any given
Product, regardless of the number of indications sought (or approvals
obtained) for such Product, whether alone or in combination with other
products, and regardless of any new dosage strengths, preparations or
forms of administration for such Product.
7.2.3 If Incyte develops as a back-up Product that inhibits or
otherwise modulates the activity of a particular molecular target of a
Product on which Incyte is already making milestone payments, then
Incyte may conduct clinical development on such back-up or follow-on
Products and shall not be obligated to make any milestone payments with
respect to any such back-up or follow-on Product, except as otherwise
provided below. In the event that a particular Product is dropped from
active clinical development work or marketing for safety or efficacy
reasons and is specifically replaced
22
24
with a different Product targeting the same molecular target as such
dropped Product, such new Product shall be deemed a "Replacement
Product." Incyte shall not be obligated to make milestone payments that
were earlier made with respect to a dropped Product and replaced by a
Replacement Product, but, subject to Section 7.2.2, Incyte shall pay
all milestone payments for milestone events achieved by such
Replacement Product that had not been achieved by such dropped Product.
7.3 Royalties Payable by Incyte.
7.3.1 Royalties on Net Sales. In consideration of the licenses
granted to Incyte under Section 3.1, Incyte shall pay to Lexicon a
royalty of [**] on cumulative Net Sales of each Product by Incyte, its
Affiliates and its Corporate Partners.
7.3.2 Royalty Reports; Exchange Rates. During the term of this
Agreement following the First Commercial Sale of any Product, Incyte
shall, within [**] after each calendar quarter, furnish to Lexicon a
written quarterly report showing: (i) the gross sales and Net Sales of
Products sold by Incyte and its Affiliates and Corporate Partners
during the reporting period and the calculation of Net Sales from such
gross sales; (ii) the royalties payable in United States dollars which
shall have accrued hereunder in respect of such Net Sales; (iii)
withholding taxes, if any, required by law to be deducted in respect of
such royalties; (iv) the dates of the First Commercial Sales of
Products in any country during the reporting period; and (v) the
exchange rates used in determining the amount of United States dollars
payable hereunder. Royalties payable on sales in countries other than
the United States shall be calculated in accordance with the standard
exchange rate conversion practices used by Incyte for financial
accounting purposes. If no royalty or payment is due for any royalty
period hereunder, Incyte shall so report. Incyte shall keep, and shall
require its Corporate Partners to keep (all in accordance with
generally accepted accounting principles, consistently applied),
complete and accurate records in sufficient detail to properly reflect
all gross sales and Net Sales and to enable the royalties payable
hereunder to be determined.
7.3.3 Audits. Upon the written request of Lexicon, Incyte
shall permit an independent certified public accountant selected by
Lexicon and acceptable to Incyte, which acceptance shall not be
unreasonably withheld, to have access, at reasonable times and during
normal business hours, to such records of Incyte as may be reasonably
necessary to verify the accuracy of the royalty reports described
herein, in respect of any fiscal year ending not more than [**] prior
to the date of such request. Lexicon and Incyte shall use commercially
reasonable efforts to schedule all such verifications within [**] after
Lexicon makes its written request. All such verifications shall be
conducted not more than once in, or with respect to, each calendar
year. The report of Lexicon's independent certified public accountant
shall be made available to both parties. Subject to Incyte's rights
under Section 13.6, in the event Lexicon's independent certified public
accountant [**] concludes that additional royalties were owed to
Lexicon for such period, the additional royalty shall be paid by Incyte
within [**] of the date Lexicon delivers to Incyte such independent
certified public accountant's written report so concluding. In the
event Lexicon's independent certified public accountant [**] concludes
that there was an overpayment of royalties to Lexicon during such
period, the overpayment shall be
23
25
repaid by Lexicon within [**] of the date Lexicon received such
independent certified public accountant's written report so concluding.
The fees charged by such independent certified public accountant shall
be paid by Lexicon unless such audit discloses an underpayment of more
than [**] of the amount due under this Agreement for the period in
question, in which case Incyte will bear the full cost of such audit.
Incyte shall include in each agreement with each applicable Corporate
Partner a provision requiring the Corporate Partner to make reports to
Incyte, to keep and maintain records of sales made pursuant to such
agreement and to grant access to such records by Lexicon's independent
certified public accountant to the same extent required of Incyte under
this Agreement. Lexicon agrees that all information subject to review
under this Section 7.3.3 or under any agreement with a Corporate
Partner of Incyte is confidential and that Lexicon shall cause its
independent certified public accountant to retain all such information
in confidence. Lexicon's independent certified public accountant shall
only report to Lexicon as to the computation of the royalties and other
payments due to Lexicon under this Agreement and shall not disclose to
Lexicon any other information of Incyte or its Corporate Partner.
7.3.4 Royalty Payment Terms. Royalty payments for each
calendar quarter shall be due at the time Incyte's report under Section
7.3.2 for such calendar quarter shall be due.
7.4 Fees for Development of Mutant Mice. The following fees shall be
payable for Mutant Mice requested by Incyte pursuant to Section 5.2:
(a) [**] for each line of Mutant Mice requested by Incyte
pursuant to Section 5.2 and delivered by Lexicon, which shall be
payable within [**] after Lexicon's notice that Mutant Mice from such
line are available for shipment to Incyte; [**] and
(b) An additional license and development fee of [**] for each
line of Mutant Mice with a conditional allele incorporating Cre-Lox
Technology, which shall be payable within [**] after Lexicon's notice
that Mutant Mice from such line are available for shipment to Incyte;*]
7.5 Fees for Use of LexVision Data to Support Incyte Patents. Incyte
shall pay Lexicon a fee of [**] for each Drug Target for which Incyte uses data
or other information from the LexVision Database pursuant to Section 3.2.
7.6 Fees for Drug Target Licenses following the Collaboration Term.
Upon termination or expiration of the Collaboration Term, to retain any license
under Section 3.1.3, Incyte shall, on a Designated Drug Target-by-Designated
Drug Target basis, pay Lexicon an annual license maintenance fee of [**] until:
(a) the filing by Incyte of an IND for a Product related to
such Designated Drug Target, in which case the license under Section
3.1.3 with respect to such Designated Drug Target shall then extend in
perpetuity; or
24
26
(c) the license is terminated prior to the filing of an IND by
Incyte for a Product related to such Designated Drug Target, on a given
anniversary of the Collaboration Term, by Incyte's delivery of written
notice of such termination to Lexicon.
7.7 Withholding Taxes. In the event that any royalties or other
payments due to Lexicon are subject to withholding tax required by law to be
paid to the taxing authority of any foreign country, the amount of such tax may
be withheld from the applicable royalties or other payment due Lexicon. Incyte
shall promptly pay such tax on behalf of Lexicon and shall furnish Lexicon with
a certificate of withholding tax so deducted for Lexicon's avoidance of
duplicate taxation in United States. Incyte may not deduct any other withholding
or any other governmental charges from the payments agreed upon under this
Agreement, except to the extent same are paid on behalf of, or for the benefit
of, Lexicon. Incyte shall maintain official receipts of payment of any such
withholding taxes and shall forward such receipts to Lexicon.
7.8 Blocked Currency. If by law, regulation, or fiscal policy of a
particular country, conversion into United States dollars or transfer of funds
of a convertible currency to the United States is restricted or forbidden,
Incyte shall give Lexicon prompt written notice and shall pay the royalty due
under this Article 7 through such means or methods as are lawful in such country
as Lexicon may reasonably designate. Failing the designation by Lexicon of such
lawful means or methods within [**] after such written notice is given to
Lexicon, Incyte shall deposit such royalty payment in local currency to the
credit of Lexicon in a recognized banking institution designated by Lexicon, or
if none is designated by Lexicon within the [**] period described above, in a
recognized banking institution selected by Incyte and identified in a written
notice to Lexicon by Incyte, and such deposit shall fulfill all obligations of
Incyte to Lexicon with respect to such royalties.
7.9 Interest on Late Payments. Lexicon shall have the right to seek to
collect interest on any payments that are not paid on or before [**] after the
date such payments are due under this Agreement at a rate of [**] per month,
calculated on the total number of days payment is delinquent; provided, however,
that interest shall not accrue pursuant to this Section 7.9 on any amounts
payable under this Agreement with respect to which payment is disputed in good
faith; provided, further that interest shall accrue pursuant to this Section 7.9
in the event such dispute has been resolved in Lexicon's favor if payment is not
made promptly thereafter.
7.10 Manner of Payment. Except as provided in Section 7.8, payments to
be made by Incyte to Lexicon under this Agreement shall be payable in United
States dollars and shall be paid by check delivered to Lexicon at its principal
office at The Woodlands, Texas or bank wire transfer in immediately available
funds to such bank account in the State of Texas as is designated in writing by
Lexicon from time to time.
ARTICLE 8. INTELLECTUAL PROPERTY
8.1 Ownership of Intellectual Property.
25
27
8.1.1 Ownership by Lexicon of the LexVision and OmniBank
Databases and the OmniBank Library. Subject to the rights and licenses
granted under this Agreement, Lexicon (and its licensors, as
applicable) shall own and retain all rights to: (i) the LexVision and
OmniBank Databases and all information contained therein; and (ii) the
OmniBank Library, and all embryonic stem cells, genes and mutated
genes, lox sites and other biological materials contained therein.
8.1.2 Ownership of Mutant Mice and Progeny. Subject to the
rights and licenses granted under this Agreement, Lexicon shall own and
retain all rights to the Mutant Mice and any successive generations
thereof, including without limitation the right to use, produce, breed,
sell or license the Mutant Mice or any successive generations thereof,
to use any cells or genes derived by Lexicon from the Mutant Mice or
any successive generations thereof, and to use the Lexicon Technology;
[**].
8.1.3 Ownership of Inventions Arising from S-T-V Projects.
Subject to the rights and licenses granted under this Agreement,
Lexicon shall own and retain all rights to any Invention that is
conceived or first reduced to practice by Lexicon or any of its
Affiliates during the course of any S-T-V Project performed under this
Agreement.
8.1.4 Ownership of Inventions Arising from Further Incyte
Development. As between the parties, and subject to the provisions of
Sections 3.5 and 3.6, Incyte shall own and retain all rights to any
Invention that is conceived or first reduced to practice by Incyte or
any of its Affiliates, Academic Collaborators or Corporate Partners
during the course of any further development by any of them of, or
based upon, any data or results included in the LexVision or OmniBank
Databases and/or provided by Lexicon in connection with any S-T-V
Project performed under this Agreement.
8.1.5 Ownership of Inventions Arising from Further Lexicon
Development; Disclosure. In the event Lexicon chooses to engage in
further development of Level 1 S-T-V analytical data or results other
than as part of a Xxxxx 0 xxx/xx Xxxxx 0 X-X-X Project in collaboration
with Incyte, then, subject to the provisions of Section 3.5, Lexicon
shall own and retain all rights to any Invention that Lexicon conceives
or first reduces to practice during the course of such further
development.
8.1.6 Ownership of Other Intellectual Property. Subject to
Article 3 and Sections 8.1.1 through 8.1.5, (i) each party shall own
and retain all rights to all Inventions which are not Joint Inventions
and which are conceived or reduced to practice solely by its employees,
Affiliates or agents, and (ii) the parties shall jointly own all Joint
Inventions, and each owner of a Joint Invention shall have and retain
sole and exclusive title to its interest in such Joint Invention;
provided, that, the responsibility for patent filing with respect to
each Joint Invention developed hereunder shall be as set forth in
Section 8.2.
8.2 Responsibility for Patents.
8.2.1 Solely Owned Inventions. Each party shall have the
right, but not the obligation, at its sole expense, to prepare, file,
prosecute and maintain any patent
26
28
applications, patents, registration of copyrights or other intellectual
property rights directed to any Invention owned solely by such party.
8.2.2 Jointly Owned Inventions. The Steering Committee shall
determine whether, and in what jurisdictions, to seek patent protection
with respect to any Joint Invention. Lexicon shall have the first right
to assume responsibility at its sole expense for the preparation,
filing, prosecution and maintenance of any patent applications and
patents, or registration of copyright or other intellectual property
rights directed to Joint Inventions, keeping Incyte reasonably informed
of, and consulting with Incyte with respect to, all significant actions
relating thereto, and allowing Incyte to reasonably participate
therein, at its own expense. If Lexicon elects not to assume such
responsibility, Incyte shall have the right to do so at its sole
expense, keeping Lexicon reasonably informed of, and consulting with
Lexicon with respect to, all significant actions relating thereto, and
allowing Lexicon to reasonably participate therein, at its own expense.
8.3 Patent Enforcement; Infringement. Each party shall have the right,
but not the obligation, to take action against any Third Party who is, or is
allegedly, infringing any patent contemplated by this Agreement that such party
owns hereunder. Each party shall promptly inform the other party of any such
infringement or alleged infringement of such other party's patents, to the
extent the first party is aware of same. In the event a party's exercise of any
of the rights granted to it hereunder gives rise to a claim of infringement of a
patent owned by a Third Party, the Steering Committee (or, if no Steering
Committee is then in existence, the Chief Executive Officer of Incyte, or such
other appropriate officer of Incyte, and the Chief Executive Officer of Lexicon,
or such other appropriate officer of Lexicon) shall confer and agree upon the
best method for responding to and/or defending against such claim and how the
costs thereof and the payment of any damages (and, in the event of any
counterclaims, the receipt of any damages) with respect thereto shall be
allocated between the parties. Any such determination shall take into account
each party's significant interest in controlling any defense of a claim made
against itself and the respective parties' indemnification obligations under
Article 11.
ARTICLE 9. CONFIDENTIALITY
9.1 Nondisclosure Obligations.
9.1.1 General. Except as otherwise provided in this Article 9,
during the term of this Agreement and for a period of five years
thereafter, each Receiving Party shall maintain the Confidential
Information of each Disclosing Party in confidence and use it only for
purposes specifically authorized under this Agreement.
9.1.2 Limitations. To the extent it is reasonably necessary or
appropriate to fulfill its obligations or exercise its rights under
this Agreement and subject to advance written notification to the
Disclosing Party: (i) a party may disclose to Third Parties
Confidential Information it is otherwise obligated not to disclose
under this Section 9.1, to its Affiliates, Corporate Partners,
consultants, outside contractors and clinical
27
29
investigators, on a strict need-to-know basis for the purposes
contemplated by this Agreement and on condition that such entities or
persons agree to keep the Confidential Information confidential for the
same time periods and to the same extent as such party is required to
keep the Confidential Information confidential hereunder; and (ii) a
party or its Corporate Partners may disclose, using appropriate
measures to preserve confidentiality, such Confidential Information to
government or other regulatory authorities to the extent that such
disclosure is reasonably necessary to obtain authorizations to conduct
clinical trials of, and to commercially market, Products pursuant to
this Agreement. Furthermore, a Receiving Party may request permission
from the Disclosing Party to disclose such Confidential Information to
the extent that such disclosure is reasonably necessary to obtain
patents which such Receiving Party is permitted to obtain hereunder,
which permission shall not be unreasonably withheld or delayed.
9.1.3 Required Disclosure. A Receiving Party may disclose
Confidential Information pursuant to interrogatories, requests for
information or documents, subpoena, civil investigative demand issued
by a court or governmental agency or as otherwise required by law;
provided, however, that the Receiving Party shall notify the Disclosing
Party promptly upon receipt thereof, giving (where practicable) the
Disclosing Party sufficient advance notice to permit it to oppose,
limit or seek confidential treatment for such disclosure; and provided,
further, that the Receiving Party shall furnish only that portion of
the Confidential Information which it is advised by counsel is legally
required whether or not a protective order or other similar order is
obtained by the Disclosing Party.
9.2 Injunctive Relief. The parties hereto understand and agree that
remedies at law may be inadequate to protect against any breach of any of the
provisions of this Article 9 by either party or their employees, agents,
officers or directors or any other person acting in concert with it or on its
behalf. Accordingly, each party shall be entitled to the granting of injunctive
relief by a court of competent jurisdiction against any action that constitutes
any such breach of this Article 9.
9.3 Publication. Incyte and/or Lexicon (each, a "Submitting Party") may
each publish or present data and/or results generated utilizing Mutant Mice or
Progeny, subject to the prior review of the proposed disclosure by the other
party (each, a "Reviewing Party"), solely to determine (i) whether the proposed
disclosure contains the Confidential Information of the Reviewing Party or (ii)
whether information contained in the proposed disclosure should be the subject
of a patent application to be filed by the Reviewing Party prior to such
disclosure. Each Submitting Party shall provide the Reviewing Party with the
opportunity to review any proposed abstract, manuscript or presentation which
discloses the results of research conducted utilizing the Mutant Mice or Progeny
by delivering a copy thereof to the Reviewing Party no less than [**] before its
intended submission for publication or presentation. The Reviewing Party shall
have [**] from its receipt of any such abstract, manuscript or presentation in
which to notify the Submitting Party in writing of any specific objections to
the disclosure, based on either the need to seek patent protection or concern
regarding the specific disclosure of the Confidential Information of the
Reviewing Party. In the event the Reviewing Party objects to the disclosure, the
Submitting Party agrees not to submit the publication or abstract or make the
presentation
28
30
containing the objected-to information until the Reviewing Party is given a
reasonable additional period of time (not to exceed an additional [**]) to seek
patent protection for any material in the disclosure which the Reviewing Party
believes is patentable (subject, in all events, to Section 8.2) or, in the case
of Confidential Information, to allow the Submitting Party to delete any
Confidential Information of the Reviewing Party from the proposed disclosure.
The Submitting Party agrees to delete from the proposed disclosure any
Confidential Information of the Reviewing Party upon request.
ARTICLE 10. REPRESENTATIONS AND WARRANTIES
10.1 Representations, Warranties and Covenants of Lexicon. Lexicon
represents and warrants to and covenants with Incyte that:
10.1.1 Lexicon is a corporation duly organized, validly
existing and in corporate good standing under the laws of Delaware;
10.1.2 Lexicon has the corporate and legal right, authority
and power to enter into this Agreement, and to extend the rights and
licenses granted to Incyte in this Agreement;
10.1.3 Lexicon has taken all necessary action to authorize the
execution, delivery and performance of this Agreement;
10.1.4 upon the execution and delivery of this Agreement, this
Agreement shall constitute a valid and binding obligation of Lexicon,
enforceable in accordance with its terms, except as enforceability may
be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors' and contracting
parties' rights generally and except as enforceability may be subject
to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law);
10.1.5 the performance of Lexicon's obligations under this
Agreement will not conflict with its charter documents or result in a
breach of any agreements, contracts or other arrangements to which it
is a party; and
10.1.6 Lexicon will not during the term of this Agreement
enter into any agreements, contracts or other arrangements that would
be inconsistent with its obligations under this Agreement.
10.2 Representations, Warranties and Covenants of Incyte. Incyte
represents and warrants to and covenants with Lexicon that:
10.2.1 Incyte is a corporation duly organized, validly
existing and in corporate good standing under the laws of the state of
Delaware;
29
31
10.2.2 Incyte has the corporate and legal right, authority and
power to enter into this Agreement, and to extend the rights and
licenses granted to Lexicon in this Agreement;
10.2.3 Incyte has taken all necessary action to authorize the
execution, delivery and performance of this Agreement;
10.2.4 upon the execution and delivery of this Agreement, this
Agreement shall constitute a valid and binding obligation of Incyte
enforceable in accordance with its terms, except as enforceability may
be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors' and contracting
parties' rights generally and except as enforceability may be subject
to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law);
10.2.5 the performance of its obligations under this Agreement
will not conflict with Incyte's charter documents or result in a breach
of any agreements, contracts or other arrangements to which it is a
party; and
10.2.6 Incyte will not after the Effective Date enter into any
agreements, contracts or other arrangements that would be inconsistent
with its obligations under this Agreement.
10.3 Limited Warranties Relating to Performance of the LexVision and
OmniBank Databases. Lexicon warrants that the LexVision and OmniBank Databases
made available to Incyte under this Agreement from time to time shall represent
the latest version of the LexVision and OmniBank Databases which Lexicon has
made available at each such time to subscribers to the LexVision and OmniBank
Databases. Lexicon does not represent that the operations of the LexVision and
OmniBank Databases will be trouble-free or that the LexVision or OmniBank
Databases contain no errors. Lexicon is, however, obligated to Incyte, with
respect to the LexVision and OmniBank Databases, to periodically update the
LexVision and OmniBank Databases as provided in this Agreement and make every
reasonable effort to resolve any technical difficulties in a timely manner, as
further provided in Section 4.3.
10.4 Limited Warranties Relating to the Development of Mutant Mice.
Except as otherwise expressly provided in this Agreement, Lexicon represents
that it will use commercially reasonable efforts to produce Mutant Mice upon
request by Incyte. Lexicon does not represent that in all cases it will be
commercially and technically feasible to produce such Mutant Mice. Lexicon's
only obligation to Incyte with respect to the production of Mutant Mice will be
to use commercially reasonable efforts to produce such Mutant Mice as requested
by Incyte and to consult with the Steering Committee in the event of any
material difficulty.
10.5 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO THE LEXVISION
DATABASE, THE OMNIBANK DATABASE, ANY MUTANT MOUSE, PROGENY, PATENT RIGHTS,
GOODS, SERVICES OR ANY OTHER SUBJECT MATTER OF THIS AGREEMENT, AND EACH PARTY
HEREBY DISCLAIMS WARRANTIES OF
30
32
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH
RESPECT TO ANY AND ALL OF THE FOREGOING. IN ADDITION, INCYTE ACKNOWLEDGES THAT
THE LEXVISION DATABASE AND THE OMNIBANK DATABASE MAY CONTAIN INFORMATION THAT IS
COVERED BY ONE OR MORE VALID PATENTS OF THIRD PARTIES, AND THAT THE USE OF A
MUTANT MOUSE OR PROGENY MAY BE COVERED BY ONE OR MORE VALID PATENTS OF THIRD
PARTIES. EACH PARTY ACKNOWLEDGES THAT EXERCISE BY IT OF THE RIGHTS AND LICENSES
GRANTED TO IT PURSUANT TO ARTICLE 3 HEREOF MAY BE COVERED BY ONE OR MORE VALID
PATENTS OF THIRD PARTIES.
10.6 Limited Liability. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT
OR OTHERWISE TO THE CONTRARY, NEITHER LEXICON NOR INCYTE WILL BE LIABLE WITH
RESPECT TO ANY MATTER ARISING UNDER THIS AGREEMENT UNDER ANY CONTRACT,
NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY
PUNITIVE, EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOST PROFITS.
ARTICLE 11. INDEMNITY
11.1 Incyte Indemnity Obligations. Incyte agrees to defend, indemnify
and hold Lexicon, its Affiliates and their respective employees and agents
harmless from all claims, losses, damages or expenses (including reasonable
attorneys' fees and costs of litigation) arising as a result of: (i) actual or
asserted violations of any applicable law or regulation by Incyte, its
Affiliates or Corporate Partners by virtue of which any Products manufactured,
distributed or sold hereunder shall be alleged or determined to be adulterated,
misbranded, mislabeled or otherwise not in compliance with any applicable law or
regulation; (ii) claims for bodily injury, death or property damage attributable
to the manufacture, distribution, sale or use of any Products by Incyte, its
Affiliates or Corporate Partners; (iii) a Product recall ordered by a
governmental agency or required by a confirmed Product failure as reasonably
determined by the parties hereto; or (iv) Incyte's breach of any of its
representations, warranties or covenants hereunder.
11.2 Lexicon Indemnity Obligations. Lexicon agrees to defend, indemnify
and hold Incyte, its Affiliates and their respective employees and agents
harmless from all claims, losses, damages or expenses (including reasonable
attorneys' fees and costs of litigation) arising as a result of (i) the
infringement of any issued patent or valid copyright of any Third Party as a
result of Lexicon's delivery to Incyte of access to the LexVision or OmniBank
Databases or any Mutant Mouse, or the use by Incyte of the LexVision or OmniBank
Databases or any Mutant Mouse, pursuant to this Agreement, or (ii) Lexicon's
breach of any of its representations, warranties or covenants hereunder. In the
event that any claim of infringement under clause (i) of this Section 11.2 is,
or in Lexicon's judgment is likely to be, substantiated, Lexicon will use all
commercially reasonable efforts to obtain a license from the applicable Third
Party to permit the parties to continue to engage in the allegedly infringing
activities (hereinafter the "Infringing Activities"). If, after all commercially
reasonable efforts, Lexicon is unable to effect a satisfactory solution to any
such infringement claim regarding the Infringing Technology,
31
33
Lexicon will have the right to terminate Incyte's rights under this Agreement
solely with respect to the Infringing Activities.
11.3 Limitation on Indemnity Obligations. Neither party, its Affiliates
or their respective employees and agents shall be entitled to the indemnities
set forth in Sections 11.1 or 11.2, respectively, to the comparative extent the
claim, loss, damage or expense for which indemnification is sought was caused by
a grossly negligent, reckless or intentional act or omission by such party, its
directors, officers, employees or authorized agents.
11.4 Procedure. If a party or any of its Affiliates or their respective
employees or agents (collectively, the "Indemnitee") intends to claim
indemnification under this Article 11, the Indemnitee shall promptly notify the
other party (the "Indemnitor") of any loss, claim, damage, liability or action
in respect of which the Indemnitee intends to claim such indemnification, and
the Indemnitor shall assume the defense thereof with counsel selected by the
Indemnitor and reasonably acceptable to the Indemnitee, provided, however, that
an Indemnitee shall have the right to retain its own counsel, with the fees and
expenses to be paid by the Indemnitee, if representation of such Indemnitee by
the counsel retained by the Indemnitor would be inappropriate due to actual or
potential differing interests between such Indemnitee and any other party
represented by such counsel in such proceedings. The Indemnitor shall have the
right to settle or compromise any claims for which it is providing
indemnification under this Article 11, provided that the consent of the
Indemnitee (which shall not be unreasonably withheld or delayed) shall be
required in the event any such settlement or compromise would adversely affect
the interests of the Indemnitee. The indemnity agreement in this Article 11
shall not apply to amounts paid in settlement of any loss, claim, damage,
liability or action if such settlement is effected without the consent of the
Indemnitor. The failure to deliver notice to the Indemnitor within a reasonable
time after the commencement of any such action, if prejudicial to the
Indemnitor's ability to defend such action, shall relieve such Indemnitor of any
liability to the Indemnitee under this Article 11, but the omission so to
deliver notice to the Indemnitor will not relieve it of any liability that it
may have to any Indemnitee otherwise than under this Article 11. The Indemnitee
under this Article 11, its employees and agents, shall cooperate fully with the
Indemnitor and its legal representatives in the investigation of any action,
claim or liability covered by this indemnification.
11.5 Insurance. Incyte shall maintain appropriate liability insurance
(and/or self-insurance) with respect to development, manufacture and sale of
Products by Incyte in such amount as Incyte customarily maintains with respect
to sales of its other products. Incyte shall maintain such insurance for so long
as it continues to manufacture or sell Products, and thereafter for so long as
Incyte customarily maintains insurance with respect to sales of its other
products.
ARTICLE 12. EXPIRATION AND TERMINATION
12.1 Collaboration Term.
12.1.1 Expiration. Unless this Agreement is sooner terminated
in accordance with the provisions of this Article 12, the Collaboration
Term shall commence on the Effective Date and shall expire on December
31, 2005; provided that the Collaboration
32
34
Term may be extended upon the election of both parties by a written
agreement having terms mutually agreeable to both parties.
12.1.2 Optional Termination. Either party shall have the
right, in its sole discretion, to terminate the Collaboration Term on
the third anniversary of the Effective Date by delivering [**] advance
written notice of such termination to the other party.
12.1.3 Effect of Expiration or Termination of Collaboration
Term. Following the expiration or earlier termination of the
Collaboration Term, Lexicon shall have no further obligation under this
Agreement to provide to Incyte (i) updates to the LexVision or OmniBank
Databases or any additional information of any nature relating thereto,
(ii) any support services with respect to the LexVision or OmniBank
Databases, except as the parties may further agree in writing, or (iii)
any Mutant Mice (except for Mutant Mice ordered prior to the expiration
of Incyte's right to order same, as provided in Section 5.2) or the
conduct of any S-T-V Project (except for S-T-V Projects commenced prior
to the expiration of the Collaboration Term). Upon expiration of the
Collaboration Term, Incyte shall discontinue use of the LexVision and
OmniBank Databases in the Research Field and shall remove any portions
of the LexVision and OmniBank Databases from all computers at all sites
on which such information may have been installed by Incyte except as
reasonably necessary to exercise its continuing rights as set forth
below. Incyte shall be entitled to continue to use the LexVision and/or
OmniBank Databases in the Research Field for a reasonable period of
time after the termination or expiration of the Collaboration Term, for
the purposes contemplated by this Agreement, in the event that Lexicon
is required to provide any deliverables to Incyte after the expiration
of the Collaboration Term and use of the LexVision and/or OmniBank
Databases is reasonably necessary or desirable for Incyte's utilization
of such deliverables. [**]Incyte may retain, and continue to use,
copies of information from the LexVision and/or OmniBank Databases with
respect to Designated Drug Targets for which it shall retain continuing
rights under Section 3.1.3, subject to Incyte's compliance with the
surviving terms and conditions of this Agreement. The expiration or
termination of the Collaboration Term shall not affect Incyte's right
to continue to exercise its rights under Sections 3.1.4 and 3.1.5 with
respect to any Mutant Mice delivered by Lexicon hereunder, subject to
Incyte's compliance with the surviving terms and conditions of this
Agreement.
12.2 Expiration. Unless this Agreement is sooner terminated in
accordance with the provisions of this Article 12, this Agreement shall
expire and the licenses granted by Lexicon to Incyte hereunder shall
become fully paid, on a Product-by-Product and country-by-country
basis, on the latest to occur of (i) [**] after the Effective Date,
(ii) [**] after the First Commercial Sale of the relevant Product in
such country or, (iii) upon the last to expire of any Valid Claim
included in the Product Patent Rights and/or the Lexicon Patent Rights
with respect to the Designated Drug Target relating thereto in such
country.
12.3 Events of Default.
12.3.1 Default by Either Party. An Event of Default by either
party shall have occurred upon (i) the occurrence of a material breach
of this Agreement if such party fails to remedy such breach within [**]
after written notice thereof by the non-breaching party
33
35
(or, if remediation of such breach in [**] is not practicable, if such
party fails to commence and diligently pursue such remediation during
such [**] period), or (ii) the commencement of any proceeding in or for
bankruptcy, insolvency, dissolution or winding up by or against such
party that is not dismissed or otherwise disposed of within [**]
thereafter.
12.3.2 Default by Lexicon. For the avoidance of doubt, the
entry against Lexicon of, or the entry into by Lexicon of, any
judgment, decree, injunction, consent order, settlement agreement,
cross-license or any other binding obligation, unappealable or
unappealed during the time permitted for appeal (if applicable), that
has the effect of materially adversely affecting Incyte's exercise of
its rights under this Agreement shall constitute an Event of Default by
Lexicon, unless Incyte has consented thereto, in writing, in advance.
12.3.3 Default by Incyte. For the avoidance of doubt, an Event
of Default shall have occurred if Incyte fails to make any payments due
hereunder, within [**] after Lexicon delivers written notice thereof to
Incyte specifying such failure and its claim of right to terminate,
unless Incyte makes such payments plus interest, calculated in
accordance with Section 7.9, within such [**] period.
12.4 Effect of an Event of Default.
12.4.1 Remedies Available to Lexicon. If an Event of Default
occurs relating to Incyte, Lexicon shall have the right, at its option
exercisable in its sole discretion, in addition to any other rights or
remedies available to it at law or in equity and subject to the
limitations set forth in Sections 2.4.2, 10.6 and 13.6 hereof, to
terminate this Agreement upon [**] notice thereof to Incyte, in which
case (i) Incyte shall discontinue use of the LexVision and OmniBank
Databases, (ii) Incyte shall return to Lexicon, or, upon Lexicon's
written instruction, destroy all information, materials or
documentation provided by Lexicon pursuant to this Agreement,
including, without limitation, any materials derived from the LexVision
or the OmniBank Databases and all information relating thereto and any
copies thereof (including electronic copies) and (iii) Incyte shall
return to Lexicon, or, upon Lexicon's written instruction, destroy all
Mutant Mice and any Progeny thereof.
12.4.2 Remedies Available to Incyte. In the event that an
Event of Default occurs relating to Lexicon, Incyte shall have the
right, at its option exercisable in its sole discretion, in addition to
any other rights or remedies available to it at law or in equity and
subject to the limitations set forth in Sections 2.4.2, 10.6 and 13.6
hereof, to terminate this Agreement upon notice thereof to Lexicon, in
which case the rights and licenses granted to Incyte pursuant to
Sections 3.1.2 and 3.1.3 shall, subject to Incyte's obligations to pay
milestones and royalties pursuant to Article 7, continue.
12.5 Effect of Expiration or Termination of Agreement. The expiration
or termination of this Agreement shall not relieve the parties of any obligation
accruing prior to such expiration or termination. The provisions of Articles 8,
9, 10, 11 and 12, and Sections 3.1.3, 3.5 and 13.2 through 13.6 hereof shall
survive the expiration or termination of this Agreement. The
34
36
provisions of Sections 7.2 through 7.10 hereof shall survive any termination of
this Agreement under which Incyte retains the right to sell Products until such
time as this Agreement would have expired with respect to any Product, as the
case may be, in any country pursuant to Section 12.2 hereof had this Agreement
not been earlier terminated.
ARTICLE 13. MISCELLANEOUS
13.1 Force Majeure. Neither party shall be held liable or responsible
to the other party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in fulfilling or performing any obligation under
this Agreement when such failure or delay is caused by or results from causes
beyond the reasonable control of the affected party, including but not limited
to fire, floods, embargoes, war, acts of war (whether war is declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority; provided, however, that the party so affected shall use
reasonable commercial efforts to avoid or remove such causes of nonperformance,
and shall continue performance hereunder with reasonable dispatch whenever such
causes are removed. Either party shall provide the other party with prompt
written notice of any delay or failure to perform that occurs by reason of force
majeure. The parties shall mutually seek a resolution of the delay or the
failure to perform as noted above.
13.2 Assignment. This Agreement may not be assigned or otherwise
transferred, in whole or in part, by either party without the consent of the
other party; provided, however, that either Lexicon or Incyte may, without such
consent, assign its rights and obligations under this Agreement (i) to any
Affiliate, or (ii) in connection with a merger, consolidation or sale of such
portion of a party's assets that includes rights under this Agreement to an
unrelated Third Party; provided, further, that such party's rights and
obligations under this Agreement shall be assumed by its successor in interest
in any such transaction and shall not be transferred separate from all or
substantially all of its other business assets, including those business assets
that are the subject of this Agreement. [**] Any purported assignment in
violation of the preceding sentence shall be void. Any permitted assignee shall
assume all obligations of its assignor under this Agreement, unless the parties
otherwise agree.
13.3 Severability. Each party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country or
community or association of countries. Should one or more provisions of this
Agreement be or become invalid, the parties hereto shall substitute, by mutual
consent, valid provisions for such invalid provisions which valid provisions in
their economic effect are sufficiently similar to the invalid provisions that it
can be reasonably assumed that the parties would have entered into this
Agreement with such valid provisions in lieu of such invalid provisions. In case
such valid provisions cannot be agreed upon, the invalidity of one or several
provisions of this Agreement shall not affect the validity of this Agreement as
a whole, unless the invalid provisions are of such essential importance to this
Agreement that it is to be reasonably assumed that the parties would not have
entered into this Agreement without the invalid provisions.
35
37
13.4 Notices. Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the notification parties hereto to
the other shall be in writing, delivered personally or by facsimile (and
promptly confirmed by telephone, personal delivery or courier) or courier,
postage prepaid (where applicable), addressed to such other party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor and shall be effective upon receipt by the
addressee.
If to Lexicon: Lexicon Genetics Incorporated
0000 Xxxxxxxx Xxxxxx Xxxxx
Xxx Xxxxxxxxx, Xxxxx 00000
Attention: Xxxxxx X. Xxxxx, M.D., Ph.D.
President and Chief Executive Officer
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
With a copy to:
Lexicon Genetics Incorporated
0000 Xxxxxxxx Xxxxxx Xxxxx
Xxx Xxxxxxxxx, Xxxxx 00000
Attention: Xxxxxxx X. Xxxx
Executive Vice President and General Counsel
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
If to Incyte: Incyte Genomics, Inc.
0000 Xxxxxx Xxxxx
Xxxx Xxxx, XX 00000
Attention: Xxx Xxxxxxxxx
Chief Executive Officer
Telephone: 000-000-0000
Facsimile: 000-000-0000
With a copy to:
Incyte Genomics, Inc.
0000 Xxxxxx Xxxxx
Xxxx Xxxx, XX 00000
Attention: Xxx Xxxxxxxxx
Executive Vice President and General Counsel
Telephone: 000-000-0000
Facsimile: 000-000-0000
All such communications shall be effective upon receipt.
36
38
13.5 Applicable Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware, without reference to the
conflicts of law principles thereof.
13.6 Dispute Resolution. Subject to Section 2.4.2, the parties hereby
agree that they will first attempt in good faith to resolve any controversy or
claim arising out of or relating to this Agreement promptly by negotiations. If
a controversy or claim should arise hereunder, the matter shall be referred to
an individual designated by the Chief Executive Officer (or the equivalent
position) of Lexicon and by the Chief Executive Officer (or the equivalent
position) of Incyte (the "Representatives"). If the matter has not been resolved
within [**] of the first meeting of the Representatives of the parties (which
period may be extended by mutual agreement) concerning such matter, the parties
shall be free to pursue all available recourse both at law and in equity.
13.7 Entire Agreement. This Agreement, together with the exhibits and
appendices hereto and any confidentiality agreement(s) executed in contemplation
of this Agreement, contains the entire understanding of the parties with respect
to the subject matter hereof. All express or implied agreements and
understandings, either oral or written, heretofore made are expressly merged in
and made a part of this Agreement. This Agreement may be amended, or any term
hereof modified, only by a written instrument duly executed by both parties
hereto.
13.8 Publicity. Lexicon and Incyte each agree not to disclose any terms
or conditions of this Agreement to any Third Party without consulting the other
party prior to such disclosure. Notwithstanding the foregoing, prior to
execution of this Agreement, Lexicon and Incyte shall agree upon the substance
of information that can be used as a routine reference in the usual course of
business to describe the existence and general nature of this transaction, and
Lexicon and Incyte may disclose such information without consulting the other
party. The parties may thereafter from time to time mutually agree on revisions
to material to be used as a routine reference, which revisions shall be
submitted by one party for the review and approval of the other party at least
ten (10) days prior to the anticipated use or disclosure of the revised
material, such approval not to be unreasonably withheld. The terms of this
Agreement shall be treated as the Confidential Information of Lexicon and
Incyte, and, except to the extent required by applicable law, shall not be
disclosed to anyone (except for the parties' respective employees, consultants,
agents and attorneys assisting in the review and negotiation of this Agreement
who have a need to know the terms of this Agreement) without the written
permission of Incyte or Lexicon; provided that Incyte may disclose to its
Corporate Partners that it is a subscriber to the LexVision and OmniBank
Databases; and provided, further, Incyte may disclose the restrictions imposed
on it as a subscriber to the LexVision and OmniBank Databases to the employees,
directors or officers of its Academic Collaborators, under a written
confidentiality agreement, to the extent necessary to enable such Academic
Collaborators to fulfill their obligations to Incyte under sponsored research
and other similar agreements by and between such Academic Collaborators and
Incyte. Any announcements shall first be agreed upon by the parties in writing
and may include the number of Mutant Mice to be produced hereunder. If either
party desires to release a separate announcement relating to this Agreement, it
shall first allow the other party to approve in writing such proposed
announcement; such approval shall not be unreasonably withheld or delayed.
37
39
13.9 Headings. The captions to the several Articles and Sections hereof
are not a part of this Agreement, but are merely guides or labels to assist in
locating and reading the several Articles and Sections hereof.
13.10 No Partnership. It is expressly agreed that the relationship
between Lexicon and Incyte shall not constitute a partnership, joint venture or
agency. Neither Lexicon nor Incyte shall have the authority to make any
statements, representations or commitments of any kind, or to take any action,
which shall be binding on the other, without the prior consent of the other
party to do so.
13.11 Exports. The parties acknowledge that the export of technical
data, materials or products is subject to the exporting party receiving any
necessary export licenses and that the parties cannot be responsible for any
delays attributable to export controls which are beyond the reasonable control
of either party. Lexicon and Incyte agree not to export or re-export, directly
or indirectly, any information, technical data, the direct product of such data,
samples or equipment received or generated under this Agreement in violation of
any applicable export control laws or governmental regulations. Lexicon and
Incyte agree to obtain similar covenants from their licensees, sublicensees,
Corporate Partners or corporate partners, as the case may be, and contractors
with respect to the subject matter of this Section 13.11.
13.12 Waiver. The waiver by either party hereto of any right hereunder
or the failure to perform or of a breach by the other party shall not be deemed
a waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.
13.13 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
38
40
IN WITNESS WHEREOF, the parties have caused their duly authorized
officers to execute and deliver this Agreement as of the Effective Date.
LEXICON GENETICS INCORPORATED
By: Date:
--------------------------------------- -------------------------
Xxxxxx X. Xxxxx, M.D., Ph.D.
President and Chief Executive Officer
INCYTE GENOMICS, INC.
By: Date:
--------------------------------------- -------------------------
Printed Name:
-----------------------------
Title:
------------------------------------
39
41
EXHIBIT 1.8
CRE-LOX PATENT RIGHTS
Application
Country Serial No. Patent No. Issue Date Expiry Date
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
USA 4,959,317 9/25/90 9/25/2007
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
CANADA 1,293,460 12/24/91 12/24/2008
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
IRELAND 60421 7/8/94 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
JAPAN 86/236385
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
EPO 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
AUSTRIA E0085649 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
BELGIUM 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
FRANCE 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
GREAT BRITAIN 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
GERMANY 3687734 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
GREECE 3007809 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
ITALY 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
LUXEMBOURG 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
NETHERLANDS 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
SWEDEN 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
SWITZERLAND 0 220 009 2/10/93 10/6/2006
--------------------------- -------------------- ----------------------- ---------------------- ----------------------
42
EXHIBIT 1.31
DESCRIPTION OF THE LEXVISION(TM) DATABASE
The LexVision Database is a proprietary relational database comprising
mutant mouse phenotypic data and associated information. The phenotypic
information and data present in the LexVision Database can be derived from the
study of mutant mice produced by the OmniBank method or by Homologous
Recombination. Lexicon includes data from the "Level 1" analysis of mutant mice
in the LexVision Database. Level 1 analysis is designed to identify primary
pathophysiological perturbations resulting from engineered mutations.
Level 1 analysis is intended as a first pass screen that may include:
1. [**]
43
EXHIBIT 1.36
ALLOCATION OF NET SALES IN BUNDLED TRANSACTION
With respect to Products sold in a Bundled Transaction in which Incyte
or any of its Affiliates or Corporate Partners discounts the sales price of the
Products to a greater degree than Incyte, its Affiliates or its Corporate
Partners, respectively, generally discounts the price of its other products to
such customer, the amount to be included in Net Sales of such Products shall be
calculated in accordance with the following formula:
ASP-P x N-P
NS-P = ----------------------- x BTF
(SIGMA)=1 ASP-pi x N-pi
Where:
NS-P = Amount allocated to Net Sales of the Product
ASP-P = Average Selling Price (as defined below) per
unit, during the applicable period, of the
Product when sold alone
ASP-pi = Average Selling Price per unit, during the
applicable period, of each Product or each
product other than a Product in the Bundled
Transaction when sold alone
N-P = Total number of units of Product included in
the Bundled Transaction during the applicable
period
N-pi = Total number of units (i.e., corresponding to
the same ASP-pi) of each Product or product
other than a Product included in the Bundled
Transaction during the applicable period
(SIGMA)=1 = The sum of the products of the formula ASP-pi
[ ] N-pi for each and every Product or product
other than a Product included in the Bundled
Transaction during the applicable period
BTF = The aggregate amounts paid to Incyte for the
Bundled Transaction during the applicable
period
The Average Selling Price shall be based on the actual average selling
price of the applicable Product or product other than a Product, as the case may
be, determined for the applicable period.
44
If a Product or other product is not sold separately and no bona fide
list price exists for such Product or other product, the Parties shall agree
upon an imputed bona fide list price for such Product or other product, and Net
Sales with respect thereto shall be based on such imputed list price.
45
EXHIBIT 1.38
DESCRIPTION OF THE OMNIBANK(R) LIBRARY AND OMNIBANK(R) DATABASE
The OmniBank Library is a library of mouse embryonic stem ("ES") cell
clones each containing a gene trap in a single gene. The trapped gene is
identified by a sequence tag referred to as an OST, as defined herein, which
have an average length of approximately 250 base pairs (and no fewer than 100
base pairs). The OSTs identify exons of the trapped genes and are stored in a
searchable database. Once a gene of interest has been identified, the
corresponding ES cell clone, with a specified gene trap mutation, can be
microinjected into host blastocysts to produce knockout mice to study the gene's
function.
The OmniBank mutations are created using insertional mutagenesis based
on Xxxxxxx murine leukemia virus ("MoMuLV") and other vectors. The vectors
deliver a gene trap construct to the ES cells that allows the expression of a
selectable marker gene when the vector has inserted into and trapped exons from
a gene. The gene trap vectors also provide for the semi-automated acquisition of
OSTs.
46
EXHIBIT 1.50
SEEK TARGET VALIDATION (S-T-V(TM)) PROGRAM
Level 2 analysis is designed as a continuation of the Level 1 preliminary
analysis of the pathophysiological perturbations resulting from engineered
mutations. Level 2 analysis is focused on organ and physiologic system function
and represents an exhaustive analysis of organismal physiology. Phenotypic
screen analysis under Level 2 may include any or all of the following scientific
experiments depending on the partner's needs. Additional screens and assays to
be conducted by Lexicon can be explored between the parties prior to the
initiation of Level 2 biological experiments.
LEVEL 2 - ORGAN AND PHYSIOLOGIC SYSTEMS ANALYSIS
o [**]
LEVEL 3 - PATHWAY DISCOVERY AND ANALYSIS
Level 3 analysis is designed as a continuation of the Level 1 and Level 2
analysis of the pathophysiological perturbations resulting from engineered
mutations. Level 3 analysis is designed to define biochemical pathways, identify
new drug targets and to define the biochemical mechanism of the pathophysiology
identified in the Level 1 and Level 2 analysis. [**]
47
EXHIBIT 2.1
STEERING COMMITTEE AND PROJECT COORDINATORS
Incyte Steering Committee Representatives:
1. ___________________, Initial Chairperson
2. _________________________
3. _________________________
Incyte Project Coordinator: ___________
Lexicon Steering Committee Representatives:
1. Xxx Xxxxxxx, Initial Secretary
2. Xxxxx Xxxxxxxxxx
3. Xxxxx Xxxxxx
Lexicon Project Coordinator: Xxxx Xxxxxx
48
EXHIBIT 3.7-A
MATERIAL TRANSFER AGREEMENT BETWEEN INCYTE AND A CORPORATE PARTNER
OR ACADEMIC COLLABORATOR FOR TRANSFER OF
NON-CRE-LOX MUTANT MICE PURSUANT TO SECTION 3.7
Incyte Genomics, Inc. ("Incyte") is willing to provide Material
(defined below) to _______________ ("Investigator") of ________________
("[Institution/Company]") (hereinafter collectively "Recipient") solely for the
internal research purposes as described below, under the following terms.
1. Upon execution of this agreement, Incyte shall provide to
Investigator samples of the Material. "Material" as used herein means __________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
[SPECIFY THE NON-CRE-LOX MOUSE (MOUSE OR CELL LINE)] or any cell line or progeny
derived directly or therefrom.
2. The Material will be used by Recipient solely in conducting research
under the supervision of Investigator in support of a collaborative research
project with Incyte. The Material will be used solely within Recipient's
internal facilities and will not be transferred to any third party. The Material
will be used solely for internal research purposes and for no other purpose. In
no event will the Material be used in, or used in the manufacture of, a product
for sale (or lease or other transfer of a product for consideration).
3. Recipient acknowledges the Material or its parent or progenitor has
been obtained by Incyte from Lexicon Genetics Incorporated ("Lexicon").
Recipient shall acknowledge in any publication or presentation of results of
research performed using the Material that the Material or its parent or
progenitor was obtained from Lexicon.
4. Recipient will indemnify, defend and hold harmless Incyte and
Lexicon from and against any and all claims, losses, liabilities and damages
arising from or related to the Recipient's use of the Material. THE MATERIAL IS
PROVIDED TO RECIPIENT WITHOUT ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THE USE
OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF
OTHERS.
5. Recipient agrees that any person utilizing the Material within
Institution will be advised of and shall be subject to the conditions of this
Agreement.
6. Incyte represents that it has obtained prior written permission from
Lexicon to enter into this Agreement.
49
The parties agree to the foregoing and have caused this Agreement to be
executed by their duly authorized representatives.
INCYTE GENOMICS, INC.
By:
----------------------------------
Title:
-------------------------------
Date:
--------------------------------
[Name of Institution/Company]
By:
------------------------------------ -------------------------------------
(signature of authorized representative) (signature of Investigator)
Printed Name: Printed Name:
-------------------------- ------------------------
Title:
---------------------------------
Date: Date:
---------------------------------- -------------------------------
50
EXHIBIT 3.7-B
MATERIAL TRANSFER AGREEMENT BETWEEN INCYTE AND A CORPORATE PARTNER
OR ACADEMIC COLLABORATOR FOR LOX-MUTANT MICE
PURSUANT TO SECTIONS 3.1.5.2 AND 3.7
Incyte Genomics, Inc. ("Incyte") is willing to provide Material
(defined below) to ____________________________ ("Investigator") of
____________________________ ("[Institution/Company]") (hereinafter collectively
"Recipient") solely for the internal research purposes as described below, under
the following terms.
1. Upon execution of this agreement, Incyte shall provide to
Investigator samples of the Material. "Material" as used herein means __________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
[SPECIFY THE LOX MOUSE (MOUSE OR CELL LINE) OR ANY CELL LINE OR PROGENY
CONTAINING LOX DNA DERIVED THEREFROM] and any cell line or progeny containing
lox DNA or cre DNA derived directly or indirectly therefrom.
2.1. The Material will be used by Recipient solely in conducting
research under the supervision of Investigator in support of the collaborative
research project with Incyte. The material will be used solely within
Recipient's internal facilities will not be transferred to any third party. The
Material will be used solely for internal research purposes and for no other
purpose. In no event will the Material be used in, or used in the manufacture
of, a product for sale (or lease or other transfer of a product for
consideration).
2.2. Recipient further agrees that it will not manipulate the
genetic information at any loxP site in the Material using cre recombinase,
except as may be permitted as set forth in Section 4 below. For example and
without limitation, Recipient shall not cross-breed any mouse containing loxP
with a mouse expressing cre recombinase.
3. The Material is covered by the claims of U.S. patent number
4,959,317, which is assigned to DuPont Pharmaceuticals Company. The Material or
its parent or progenitor has been obtained by Incyte from Lexicon Genetics
Incorporated ("Lexicon") which has licensed certain rights under U.S. patent
number 4,959,317 from DuPont Pharmaceuticals Company, including the right to
permit Incyte to extend to third parties the limited rights to practice under
U.S. patent number 4,959,317 as set forth herein. Except as specifically and
expressly set forth herein, no right is granted by DuPont Pharmaceuticals
Company to practice inventions claimed under U.S. patent number 4,959,317.
Recipient shall acknowledge in any publication or presentation of results of
research performed using the Material that the Material or its parent or
progenitor was obtained from Lexicon.
4. In the event that Recipient has entered into a license agreement
with DuPont Pharmaceuticals Company, The DuPont Merck Pharmaceutical Company or
X.X. XxXxxx de
51
Nemours and Company granting rights under U.S. patent number 4,959,317, then the
use of the Material shall be subject to the terms of such license agreement,
provided however, that the use of the Material shall be subject to any further
restrictions on the use of the Material as set forth herein.
5. With respect to any further license rights under U.S. patent number
4,959,317, Recipient should contact:
Vice President, Product Planning & Acquisition
DuPont Pharmaceuticals Company
000 Xxxxxx Xxxx, Xxxxxxxx Xxx Xxxxx, XX000
Xxxxxxxxxx, Xxxxxxxx 00000-0000
(fax number: 000-000-0000)
6. Recipient will indemnify, defend and hold harmless Incyte and
Lexicon from and against any and all claims, losses, liabilities and damages
arising from or related to the Recipient's use of the Material. THE MATERIAL IS
PROVIDED TO RECIPIENT WITHOUT ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THE USE
OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF
OTHERS.
7. Recipient agrees that any person utilizing the Material within
[Institution/Company] will be advised of and shall be subject to the conditions
of this Agreement.
8. Incyte represents that it has obtained prior written permission from
Lexicon to enter into this Agreement.
52
The parties agree to the foregoing and have caused this Agreement to be
executed by their duly authorized representatives.
INCYTE GENOMICS, INC.
By:
----------------------------------
Title:
-------------------------------
Date:
--------------------------------
[Name of Institution/Company]
By:
------------------------------------ -------------------------------------
(signature of authorized representative) (signature of Investigator)
Printed Name: Printed Name:
-------------------------- ------------------------
Title:
---------------------------------
Date: Date:
---------------------------------- -------------------------------
53
EXHIBIT 4.4.1
FORM FOR DESIGNATION OF LEXVISION PROJECTS
DATE
Lexicon Genetics Incorporated
Attn: LexVision Project Manager
0000 Xxxxxxxx Xxxxxx Xxxxx
Xxx Xxxxxxxxx, XX 00000
Subject: LexVision Project Initiation Request
Dear _________:
This letter is to provide notice to Lexicon Genetics Incorporated ("Lexicon") of
the request by Incyte Genomics, Inc. ("Incyte"), under Section 4.4.1 of the
LexVision
Database and Collaboration Agreement between Lexicon and Incyte dated
____________________ (the "Agreement"), that Lexicon initiate a standard mutant
mouse project specified below for inclusion in the LexVision Database, subject
to the terms and conditions of the Agreement.
The standard mutant mouse project to be initiated is described as follows:
o Gene Name:
o Method of Development:
[**]
o Mouse cDNA sequence (if known):
(Provide as an electronic file or on diskette if necessary)
o Is the genomic structure (i.e., intron/exon boundaries, size of
introns, position of initiation codon, etc.) known for this gene?
(Provide as an electronic file or on diskette if necessary)
o Description of desired mutation (i.e., which specific sequences to
delete):
Sincerely,
Name:
-------------------------------------
Incyte Project Coordinator
Title:
------------------------------------
54
EXHIBIT 5.2
REQUEST FOR DELIVERY OF LEXVISION MUTANT MOUSE UNDER SECTION 5.2
DATE
Lexicon Genetics Incorporated
Attn: LexVision Project Coordinator
0000 Xxxxxxxx Xxxxxx Xxxxx
Xxx Xxxxxxxxx, XX 00000
Subject: Request for Delivery of LexVision Mutant Mice
Dear __________:
This letter is to provide notice to Lexicon Genetics Incorporated ("Lexicon") of
the request by Incyte Genomics, Inc. ("Incyte"), under Section(s) 5.2 of the
LexVision
Database and Collaboration Agreement between Lexicon and Incyte dated
_________, 2000 (the "Agreement"), for the delivery to Incyte of the LexVision
Mutant Mice specified below, subject to the terms and conditions of the
Agreement.
o LexVision Accession No.:
o Gene Name:
[ ] The "Request for Shipping Information" form has been completed and
attached.
Sincerely,
Name:
---------------------------
Incyte Project Coordinator
Title:
--------------------------
================================================================================
FOR LEXICON USE ONLY
-------------------- ---------------------------- --------------------- ----------------------------------------------
REQUEST NO.: PROJECT I.D.:
-------------------- ---------------------------- --------------------- ----------------------------------------------
METHOD: [ ] Stock [ ] Microinjection [ ] In Vitro Fertilization
-------------------- -------------------------------------------------------------------------------------------------
DATE OF COMPLETION: ________________ PROJECT MANAGER: ____________________
55
EXHIBIT 5.5
STANDARD LEXICON MUTANT MOUSE SHIPPING AND RECEIVING REPORT
REQUEST FOR SHIPPING INFORMATION
The following information is required to process the shipment of your mutant
mice. In order to prevent any delays in shipping your mice, please complete this
form in full and submit it to Lexicon as soon as possible. Omission of any
information could delay your shipment. **Lexicon will not ship any mice without
explicit authorization from the receiving institution's veterinarian.**
SHIPPING & RECEIVING CLERK:
-----------------------------------------------
Clerk's Telephone:
-----------------------------------------------
Clerk's Fax:
-----------------------------------------------
Clerk's E-mail:
-----------------------------------------------
-----------------------------------------------
INSTITUTION:
-----------------------------------------------
SHIPPING ADDRESS:
Street
-----------------------------------------------
Building
-----------------------------------------------
Room No.
-----------------------------------------------
City, State and Zip Code
-----------------------------------------------
Country
-----------------------------------------------
INSTITUTION'S VETERINARIAN:
-----------------------------------------------
Veterinarian's Telephone:
-----------------------------------------------
Veterinarian's Fax:
-----------------------------------------------
Veterinarian's E-mail:
-----------------------------------------------
RECEIVING INVESTIGATOR:
-----------------------------------------------
Investigator's Telephone:
-----------------------------------------------
Investigator's Fax:
-----------------------------------------------
Investigator's E-mail:
-----------------------------------------------
SHIPPING & DELIVERY REQUIREMENTS (DOMESTIC AND INTERNATIONAL):
Lexicon will use the information you provide above to exchange the required
health documents with the Institution's Veterinarian and schedule the shipment.
The shipping costs have been included in the overall project cost.
INTERNATIONAL ONLY: Lexicon will contact the Receiving Veterinarian
approximately 3 weeks prior to delivery. At this time,
Lexicon will provide serology reports and request an Import
Permit from the Receiving Veterinarian. An Import Permit is
required in most countries and must be provided to Lexicon
in English and the predominant language of the receiving
country. Lexicon will notify Receiving Institution and
Animal Port Houston when mice are ready to be shipped. Upon
arrival in the destination country, the Receiving
Institution is responsible for arranging delivery from the
airport to Receiving Institution. Animal Port Houston will
contact the Receiving Institution and provide flight
information.
PLEASE RETURN THIS FORM TO: LexVision(TM) Project Manager
Lexicon Genetics Incorporated
0000 Xxxxxxxx Xxxxxx Xxxxx
Xxx Xxxxxxxxx, XX 00000
Tel: 000-000-0000
Fax: 000-000-0000
E-mail: xx@xxxxxx.xxx or xxxxxxx@xxxxxx.xxx
